|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
JP2007530029A
(ja)
*
|
2004-03-26 |
2007-11-01 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
アネキシンｉｉ及びその使用
|
|
DK1810026T3
(en)
*
|
2004-10-06 |
2018-07-16 |
Mayo Found Medical Education & Res |
B7-H1 AND PD-1 FOR TREATMENT OF RENAL CELL CARCINOM
|
|
DK2439273T3
(da)
*
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
CA2611861C
(en)
*
|
2005-06-08 |
2017-11-28 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for the treatment of persistent infections
|
|
AU2012204032B2
(en)
*
|
2005-06-08 |
2014-01-16 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
WO2007070660A2
(en)
|
2005-12-13 |
2007-06-21 |
President And Fellows Of Harvard College |
Scaffolds for cell transplantation
|
|
US8216996B2
(en)
|
2006-03-03 |
2012-07-10 |
Ono Pharmaceutical Co., Ltd. |
Multimer of extracellular domain of cell surface functional molecule
|
|
HUE059011T2
(hu)
|
2006-05-31 |
2022-09-28 |
Childrens Medical Center |
Immunmodulátorként szolgáló ABC5-pozitív mezenchimális õssejtek
|
|
KR101523391B1
(ko)
|
2006-12-27 |
2015-05-27 |
에모리 유니버시티 |
감염 및 종양 치료를 위한 조성물 및 방법
|
|
DK2155248T3
(en)
|
2007-04-12 |
2015-09-14 |
Brigham & Womens Hospital |
Targeting abcb5 for cancer therapy
|
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
|
AU2014201367B2
(en)
*
|
2007-06-18 |
2016-01-28 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor pd-1
|
|
BR122017025062B8
(pt)
*
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
US20090324609A1
(en)
*
|
2007-08-09 |
2009-12-31 |
Genzyme Corporation |
Method of treating autoimmune disease with mesenchymal stem cells
|
|
US8263078B2
(en)
|
2007-09-05 |
2012-09-11 |
Inotek Pharmaceuticals Corporation |
Antibodies against flagellin and uses thereof
|
|
CN102006891B
(zh)
|
2008-02-13 |
2017-04-26 |
哈佛学院董事会 |
连续的细胞程序化装置
|
|
EP2262837A4
(en)
*
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
|
US20110129499A1
(en)
|
2008-05-19 |
2011-06-02 |
Paulo Maciag |
Dual delivery system for heterologous antigens
|
|
JP2012500855A
(ja)
*
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
|
|
AU2009288730B2
(en)
|
2008-08-25 |
2013-06-20 |
Amplimmune, Inc. |
Compositions of PD-1 antagonists and methods of use
|
|
US9181342B2
(en)
|
2008-09-12 |
2015-11-10 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
AU2009290544B2
(en)
*
|
2008-09-12 |
2015-07-16 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
NO2344540T3
(https=)
|
2008-10-02 |
2018-04-28 |
|
|
|
PT3130923T
(pt)
*
|
2008-11-14 |
2020-06-17 |
Brigham & Womens Hospital Inc |
Métodos terapêuticos relacionados com células estaminais
|
|
US11542328B2
(en)
|
2008-11-14 |
2023-01-03 |
The Brigham And Women's Hospital, Inc. |
Therapeutic and diagnostic methods relating to cancer stem cells
|
|
MX2011005691A
(es)
|
2008-11-28 |
2011-07-20 |
Univ Emory |
Metodos para el tratamiento de infecciones y tumores.
|
|
EP3255060A1
(en)
*
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
JP5844159B2
(ja)
*
|
2009-02-09 |
2016-01-13 |
ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ |
Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
|
|
US20100239583A1
(en)
*
|
2009-03-04 |
2010-09-23 |
Inotek Pharmaceuticals Corporation |
Antibodies against flagellin and uses thereof
|
|
CN102369008B
(zh)
|
2009-03-30 |
2014-10-29 |
卫材R&D管理有限公司 |
脂质体组合物
|
|
EP2482849B1
(en)
|
2009-09-30 |
2018-06-06 |
Memorial Sloan-Kettering Cancer Center |
Combination immunotherapy for the treatment of cancer
|
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
|
US20130202623A1
(en)
*
|
2010-02-16 |
2013-08-08 |
Nicolas Chomont |
Pd-1 modulation and uses thereof for modulating hiv replication
|
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
EP2545078A1
(en)
*
|
2010-03-11 |
2013-01-16 |
UCB Pharma, S.A. |
Pd-1 antibody
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
MX374075B
(es)
*
|
2010-03-26 |
2025-03-05 |
Dartmouth College |
Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
|
|
WO2011159877A2
(en)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
|
US9783578B2
(en)
|
2010-06-25 |
2017-10-10 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
US8906649B2
(en)
|
2010-09-27 |
2014-12-09 |
Janssen Biotech, Inc. |
Antibodies binding human collagen II
|
|
ES2757857T3
(es)
|
2010-09-27 |
2020-04-30 |
Janssen Biotech Inc |
Anticuerpos de unión a colágeno II humano
|
|
WO2012138377A2
(en)
|
2010-10-01 |
2012-10-11 |
Trustees Of The University Of Pennsylvania |
The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
|
|
CN107648668B
(zh)
|
2010-10-06 |
2021-06-18 |
哈佛学院董事会 |
用于基于材料的细胞疗法的可注射的成孔水凝胶
|
|
CA2829960A1
(en)
|
2011-03-11 |
2012-09-20 |
John Rothman |
Listeria-based adjuvants
|
|
PT2691112T
(pt)
*
|
2011-03-31 |
2018-07-10 |
Merck Sharp & Dohme |
Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
|
|
EP2699603B1
(en)
|
2011-04-19 |
2016-03-02 |
The United States of America As Represented by the Secretary Department of Health and Human Services |
Human monoclonal antibodies specific for glypican-3 and use thereof
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
US9675561B2
(en)
|
2011-04-28 |
2017-06-13 |
President And Fellows Of Harvard College |
Injectable cryogel vaccine devices and methods of use thereof
|
|
WO2012168944A1
(en)
|
2011-06-08 |
2012-12-13 |
Aurigene Discovery Technologies Limited |
Therapeutic compounds for immunomodulation
|
|
AU2012275390A1
(en)
|
2011-06-28 |
2014-01-16 |
Whitehead Institute For Biomedical Research |
Using sortases to install click chemistry handles for protein ligation
|
|
EP3812387A1
(en)
|
2011-07-21 |
2021-04-28 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Heterocyclic protein kinase inhibitors
|
|
ES2893855T3
(es)
|
2011-08-11 |
2022-02-10 |
Ono Pharmaceutical Co |
Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
WO2013132317A1
(en)
|
2012-03-07 |
2013-09-12 |
Aurigene Discovery Technologies Limited |
Peptidomimetic compounds as immunomodulators
|
|
WO2013138337A1
(en)
|
2012-03-12 |
2013-09-19 |
Advaxis |
Suppressor cell function inhibition following listeria vaccine treatment
|
|
CA2868408A1
(en)
|
2012-03-29 |
2013-10-03 |
Aurigene Discovery Technologies Limited |
Immunomodulating cyclic compounds from the bc loop of human pd1
|
|
CA2869748C
(en)
|
2012-04-12 |
2017-10-24 |
Yale University |
Vehicles for controlled delivery of different pharmaceutical agents
|
|
DK2838515T3
(da)
|
2012-04-16 |
2020-02-24 |
Harvard College |
Mesoporøse siliciumdioxidsammensætninger til modulering af immunresponser
|
|
HK1203971A1
(en)
|
2012-05-15 |
2015-11-06 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
KR20220084444A
(ko)
*
|
2012-05-31 |
2022-06-21 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Pd-l1에 결합하는 항원 결합 단백질
|
|
RS58514B1
(sr)
|
2012-06-13 |
2019-04-30 |
Incyte Holdings Corp |
Supstituisana triciklična jedinjenja kao inhibitori fgfr
|
|
JP6285923B2
(ja)
|
2012-06-22 |
2018-02-28 |
トラスティーズ・オブ・ダートマス・カレッジ |
新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
KR20210008155A
(ko)
|
2012-08-30 |
2021-01-20 |
암젠 인크 |
단순 헤르페스 바이러스 및 면역 체크포인트 억제제를 사용한 흑색종의 치료방법
|
|
US9381244B2
(en)
|
2012-09-07 |
2016-07-05 |
King's College London |
VISTA modulators for diagnosis and treatment of cancer
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
WO2014122271A1
(en)
|
2013-02-07 |
2014-08-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from diffuse large b-cell lymphomas
|
|
JP6647868B2
(ja)
|
2013-02-20 |
2020-02-14 |
ノバルティス アーゲー |
ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置
|
|
US9573988B2
(en)
|
2013-02-20 |
2017-02-21 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
|
|
EP2964638B1
(en)
|
2013-03-06 |
2017-08-09 |
Astrazeneca AB |
Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
|
|
WO2014165082A2
(en)
*
|
2013-03-13 |
2014-10-09 |
Medimmune, Llc |
Antibodies and methods of detection
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
US20160084839A1
(en)
|
2013-04-02 |
2016-03-24 |
Marisa Dolled-Filhart |
Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
|
|
EP2983661B1
(en)
|
2013-04-09 |
2024-05-29 |
Lixte Biotechnology, Inc. |
Formulations of oxabicycloheptanes and oxabicycloheptenes
|
|
MX2015014438A
(es)
|
2013-04-18 |
2016-05-18 |
Armo Biosciences Inc |
Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
SMT202100065T1
(it)
*
|
2013-05-02 |
2021-03-15 |
Anaptysbio Inc |
Anticorpi diretti contro la proteina della morte programmata (pd-1)
|
|
EP2994491A4
(en)
|
2013-05-10 |
2016-12-07 |
Whitehead Inst Biomedical Res |
IN VITRO PREPARATION OF ERYTHROCYTES WITH SORTASE-PROOF PROTEINS
|
|
WO2014183066A2
(en)
|
2013-05-10 |
2014-11-13 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
|
WO2014194293A1
(en)
|
2013-05-30 |
2014-12-04 |
Amplimmune, Inc. |
Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
|
|
WO2014194302A2
(en)
|
2013-05-31 |
2014-12-04 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-1
|
|
EP3010527B1
(en)
|
2013-06-17 |
2018-08-08 |
Armo Biosciences, Inc. |
Method for assessing protein identity and stability
|
|
SG11201600853UA
(en)
|
2013-08-05 |
2016-03-30 |
Twist Bioscience Corp |
De novo synthesized gene libraries
|
|
PT3444271T
(pt)
|
2013-08-08 |
2022-01-05 |
Inst Nat Sante Rech Med |
Modulocinas baseadas em il-15 e no domínio sushi de il-15ralfa
|
|
RS59756B1
(sr)
|
2013-08-08 |
2020-02-28 |
Cytune Pharma |
Kombinovana farmaceutska kompozicija
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
AU2014309199B2
(en)
|
2013-08-20 |
2018-04-19 |
Merck Sharp & Dohme Llc |
Treating cancer with a combination of a PD-1 antagonist and dinaciclib
|
|
CN105658232A
(zh)
|
2013-08-30 |
2016-06-08 |
阿尔莫生物科技股份有限公司 |
使用白细胞介素-10治疗疾病和病症的方法
|
|
HUE038169T2
(hu)
|
2013-09-06 |
2018-09-28 |
Aurigene Discovery Tech Ltd |
1,2,4-Oxadiazol származékok mint immunomodulátorok
|
|
EA029661B1
(ru)
|
2013-09-06 |
2018-04-30 |
Ауриген Дискавери Текнолоджиз Лимитед |
Производные 1,3,4-оксадиазола и 1,3,4-тиадиазола в качестве иммуномодуляторов
|
|
HRP20181271T1
(hr)
|
2013-09-06 |
2018-10-05 |
Aurigene Discovery Technologies Limited |
Ciklički peptidomimetički spojevi kao imunomodulatori
|
|
US10077305B2
(en)
*
|
2013-09-10 |
2018-09-18 |
Medimmune Limited |
Antibodies against PD-1 and uses thereof
|
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
WO2015066413A1
(en)
|
2013-11-01 |
2015-05-07 |
Novartis Ag |
Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
|
|
CA2929277C
(en)
|
2013-11-01 |
2018-01-16 |
Yale University |
Delivery vehicles comprising il-2 and losartan
|
|
CN120242030A
(zh)
|
2013-11-11 |
2025-07-04 |
阿尔莫生物科技股份有限公司 |
将白细胞介素-10用于治疗疾病和病症的方法
|
|
US10556024B2
(en)
|
2013-11-13 |
2020-02-11 |
Whitehead Institute For Biomedical Research |
18F labeling of proteins using sortases
|
|
AU2014348657A1
(en)
|
2013-11-13 |
2016-05-19 |
Novartis Ag |
mTOR inhibitors for enhancing the immune response
|
|
US10241115B2
(en)
|
2013-12-10 |
2019-03-26 |
Merck Sharp & Dohme Corp. |
Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue
|
|
SG10201804945WA
(en)
|
2013-12-12 |
2018-07-30 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
|
EP3084003A4
(en)
|
2013-12-17 |
2017-07-19 |
Merck Sharp & Dohme Corp. |
Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
WO2015097536A2
(en)
|
2013-12-24 |
2015-07-02 |
Janssen Pharmaceutical Nv |
Anti-vista antibodies and fragments
|
|
DK3092256T3
(da)
|
2014-01-10 |
2022-06-20 |
Birdie Biopharmaceuticals Inc |
Forbindelser og sammensætninger til immunterapi
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
TWI681969B
(zh)
*
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
PE20170255A1
(es)
*
|
2014-01-24 |
2017-03-22 |
Dana Farber Cancer Inst Inc |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
|
|
HUE045065T2
(hu)
|
2014-01-31 |
2019-12-30 |
Novartis Ag |
TIM-3 antitest molekulák és felhasználásaik
|
|
PL3102605T3
(pl)
|
2014-02-04 |
2019-06-28 |
Pfizer Inc. |
Połączenie antagonisty pd-1 i inhibitora vegfr do leczenia nowotworu
|
|
SG11201606428UA
(en)
|
2014-02-04 |
2016-09-29 |
Incyte Corp |
Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
|
|
US10899840B2
(en)
|
2014-02-04 |
2021-01-26 |
Pfizer Inc. |
Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
|
|
KR20240144452A
(ko)
|
2014-03-05 |
2024-10-02 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
|
|
KR102442436B1
(ko)
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
MX373444B
(es)
|
2014-03-24 |
2020-04-30 |
Novartis Ag |
Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas.
|
|
AU2015244039B2
(en)
|
2014-04-07 |
2021-10-21 |
Novartis Ag |
Treatment of cancer using anti-CD19 chimeric antigen receptor
|
|
EP3137105A4
(en)
|
2014-04-30 |
2017-12-27 |
President and Fellows of Harvard College |
Combination vaccine devices and methods of killing cancer cells
|
|
WO2015176033A1
(en)
|
2014-05-15 |
2015-11-19 |
Bristol-Myers Squibb Company |
Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
|
AU2015264102C1
(en)
|
2014-05-23 |
2020-10-08 |
Eisai R&D Management Co., Ltd. |
Combination therapies for the treatment of cancer
|
|
KR20170005492A
(ko)
|
2014-05-28 |
2017-01-13 |
아이데닉스 파마슈티칼스 엘엘씨 |
암의 치료를 위한 뉴클레오시드 유도체
|
|
SI3148579T1
(sl)
|
2014-05-28 |
2021-07-30 |
Agenus Inc. |
Proti GITR antitelesa in postopki z njihovo uporabo
|
|
WO2015187295A2
(en)
|
2014-06-02 |
2015-12-10 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
|
PE20170441A1
(es)
|
2014-06-06 |
2017-04-26 |
Bristol Myers Squibb Co |
Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
|
|
US11123426B2
(en)
|
2014-06-11 |
2021-09-21 |
The Trustees Of Dartmouth College |
Use of vista agonists and antagonists to suppress or enhance humoral immunity
|
|
US10092645B2
(en)
|
2014-06-17 |
2018-10-09 |
Medimmune Limited |
Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
|
|
IL287519B2
(en)
*
|
2014-06-19 |
2024-01-01 |
Regeneron Pharma |
Non-human animals having a humanized programmed cell death 1 gene
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
CN121243402A
(zh)
|
2014-07-09 |
2026-01-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1组合
|
|
ES2833425T3
(es)
|
2014-07-16 |
2021-06-15 |
Roussy Inst Gustave |
Combinación de virus oncolítico con moduladores de punto de control inmunitario
|
|
RU2696312C2
(ru)
|
2014-07-16 |
2019-08-01 |
Трансген Са |
Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
|
|
CA2955612C
(en)
|
2014-07-18 |
2022-05-17 |
Advaxis, Inc. |
Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
|
|
TWI719942B
(zh)
|
2014-07-21 |
2021-03-01 |
瑞士商諾華公司 |
使用ｃｄ３３嵌合抗原受體治療癌症
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
US9982052B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
|
WO2016020836A1
(en)
|
2014-08-06 |
2016-02-11 |
Novartis Ag |
Quinolone derivatives as antibacterials
|
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
|
MX2017002205A
(es)
|
2014-08-19 |
2017-08-21 |
Novartis Ag |
Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
|
|
US10695426B2
(en)
|
2014-08-25 |
2020-06-30 |
Pfizer Inc. |
Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
|
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
US9535074B2
(en)
|
2014-09-08 |
2017-01-03 |
Merck Sharp & Dohme Corp. |
Immunoassay for soluble PD-L1
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
JP6839074B2
(ja)
|
2014-09-17 |
2021-03-03 |
ノバルティス アーゲー |
養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
|
|
US10053683B2
(en)
|
2014-10-03 |
2018-08-21 |
Whitehead Institute For Biomedical Research |
Intercellular labeling of ligand-receptor interactions
|
|
KR20170066546A
(ko)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
조합 요법
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
KR20170068504A
(ko)
|
2014-10-08 |
2017-06-19 |
노파르티스 아게 |
키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
|
|
JP6991857B2
(ja)
|
2014-10-10 |
2022-01-13 |
イデラ ファーマシューティカルズ インコーポレイテッド |
Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
|
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
WO2016060996A2
(en)
|
2014-10-14 |
2016-04-21 |
Armo Biosciences, Inc. |
Interleukin-15 compositions and uses thereof
|
|
AU2015336101A1
(en)
|
2014-10-22 |
2017-04-20 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
EP3212670B1
(en)
|
2014-10-29 |
2020-12-23 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|
|
US11236139B2
(en)
|
2014-11-05 |
2022-02-01 |
The Regents Of The University Of California |
Combination immunotherapy
|
|
EP3218409A2
(en)
*
|
2014-11-11 |
2017-09-20 |
Sutro Biopharma, Inc. |
Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
|
|
KR20230030022A
(ko)
|
2014-11-13 |
2023-03-03 |
더 존스 홉킨스 유니버시티 |
관문 차단 및 미소부수체 불안정성
|
|
TW201625692A
(zh)
|
2014-11-14 |
2016-07-16 |
諾華公司 |
抗體藥物結合物
|
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
ES2905615T3
(es)
|
2014-11-20 |
2022-04-11 |
Promega Corp |
Sistemas y métodos para evaluar moduladores de puntos de control inmunitario
|
|
PE20171324A1
(es)
|
2014-11-26 |
2017-09-11 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
EP3227335A1
(en)
|
2014-12-04 |
2017-10-11 |
Bristol-Myers Squibb Company |
Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
|
|
US10086000B2
(en)
|
2014-12-05 |
2018-10-02 |
Merck Sharp & Dohme Corp. |
Tricyclic compounds as inhibitors of mutant IDH enzymes
|
|
CA2969730A1
(en)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
|
US10508108B2
(en)
|
2014-12-05 |
2019-12-17 |
Merck Sharp & Dohme Corp. |
Tricyclic compounds as inhibitors of mutant IDH enzymes
|
|
EP3226688B1
(en)
|
2014-12-05 |
2020-07-01 |
Merck Sharp & Dohme Corp. |
Tricyclic compounds as inhibitors of mutant idh enzymes
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗ｐｄ－１抗體類和使用彼等之方法
|
|
CN113412818B
(zh)
|
2014-12-09 |
2022-11-04 |
瑞泽恩制药公司 |
具有人源化分化簇274基因的非人动物
|
|
US11377693B2
(en)
|
2014-12-09 |
2022-07-05 |
Merck Sharp & Dohme Llc |
System and methods for deriving gene signature biomarkers of response to PD-1 antagonists
|
|
DK3233843T3
(da)
|
2014-12-16 |
2019-11-18 |
Novartis Ag |
Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere
|
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
ES2948037T3
(es)
|
2014-12-18 |
2023-08-30 |
Amgen Inc |
Formulación estable congelada del virus del herpes simple
|
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
US10975442B2
(en)
|
2014-12-19 |
2021-04-13 |
Massachusetts Institute Of Technology |
Molecular biomarkers for cancer immunotherapy
|
|
PL3240801T3
(pl)
|
2014-12-31 |
2021-06-14 |
Checkmate Pharmaceuticals, Inc. |
Skojarzona immunoterapia nowotworów
|
|
CN107428818A
(zh)
|
2015-01-29 |
2017-12-01 |
密西根州立大学校董会 |
隐藏多肽及其用途
|
|
US11786457B2
(en)
|
2015-01-30 |
2023-10-17 |
President And Fellows Of Harvard College |
Peritumoral and intratumoral materials for cancer therapy
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
WO2016126615A1
(en)
|
2015-02-03 |
2016-08-11 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
EP4523756A3
(en)
|
2015-02-13 |
2025-05-28 |
Transgene |
Immunotherapeutic vaccine and antibody combination therapy
|
|
TWI712601B
(zh)
|
2015-02-20 |
2020-12-11 |
美商英塞特公司 |
作為fgfr抑制劑之雙環雜環
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
RU2714233C2
(ru)
|
2015-02-26 |
2020-02-13 |
Мерк Патент Гмбх |
Ингибиторы pd-1 / pd-l1 для лечения рака
|
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
|
AU2016226157B2
(en)
|
2015-03-04 |
2022-01-27 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and eribulin for treating cancer
|
|
SG11201707128TA
(en)
|
2015-03-06 |
2017-09-28 |
Beyondspring Pharmaceuticals Inc |
Method of treating a brain tumor
|
|
AU2016229294B2
(en)
|
2015-03-06 |
2021-11-04 |
Beyondspring Pharmaceuticals, Inc. |
Method of treating cancer associated with a RAS mutation
|
|
KR102894264B1
(ko)
|
2015-03-10 |
2025-12-02 |
오리진 온콜로지 리미티드 |
면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
|
|
EA035817B1
(ru)
|
2015-03-10 |
2020-08-14 |
Адуро Байотек, Инк. |
Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
|
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
RS60614B1
(sr)
|
2015-03-23 |
2020-08-31 |
Jounce Therapeutics Inc |
Antitela za icos
|
|
EP3770171A1
(en)
|
2015-04-03 |
2021-01-27 |
XOMA Technology Ltd. |
Treatment of cancer using inhibitors of tgf-beta and pd-1
|
|
ES2876974T3
(es)
|
2015-04-07 |
2021-11-15 |
Novartis Ag |
Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
|
|
WO2016164705A1
(en)
|
2015-04-10 |
2016-10-13 |
Omar Abdel-Rahman Ali |
Immune cell trapping devices and methods for making and using the same
|
|
AU2016249005B2
(en)
|
2015-04-17 |
2022-06-16 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3839510A3
(en)
|
2015-04-17 |
2021-08-25 |
Merck Sharp & Dohme Corp. |
Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
|
|
KR20250004095A
(ko)
|
2015-04-17 |
2025-01-07 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
|
|
US9981239B2
(en)
|
2015-04-21 |
2018-05-29 |
Twist Bioscience Corporation |
Devices and methods for oligonucleic acid library synthesis
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
JP2018514550A
(ja)
|
2015-04-28 |
2018-06-07 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
|
|
JP2018515474A
(ja)
|
2015-04-28 |
2018-06-14 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置
|
|
EP3736287A1
(en)
|
2015-05-11 |
2020-11-11 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
|
KR102608921B1
(ko)
|
2015-05-18 |
2023-12-01 |
스미토모 파마 온콜로지, 인크. |
생체 이용률이 증가된 알보시딥 프로드러그
|
|
US9708412B2
(en)
|
2015-05-21 |
2017-07-18 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
US10815264B2
(en)
|
2015-05-27 |
2020-10-27 |
Southern Research Institute |
Nucleotides for the treatment of cancer
|
|
US20180155429A1
(en)
*
|
2015-05-28 |
2018-06-07 |
Bristol-Myers Squibb Company |
Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
|
|
US20160361415A1
(en)
|
2015-05-28 |
2016-12-15 |
Armo Biosciences, Inc. |
Methods of Using Interleukin-10 for Treating Diseases and Disorders
|
|
KR20180014009A
(ko)
|
2015-05-29 |
2018-02-07 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 cpg-c 유형 올리고뉴클레오티드의 조합
|
|
MA53355A
(fr)
|
2015-05-29 |
2022-03-16 |
Agenus Inc |
Anticorps anti-ctla-4 et leurs procédés d'utilisation
|
|
WO2016196389A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
|
US20180153884A1
(en)
|
2015-05-31 |
2018-06-07 |
Curegenix Corporation |
Combination compositions for immunotherapy
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
TWI870335B
(zh)
|
2015-06-12 |
2025-01-21 |
美商宏觀基因股份有限公司 |
變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
|
|
JP2018516969A
(ja)
|
2015-06-12 |
2018-06-28 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置
|
|
EP3916018A1
(en)
*
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
MY193229A
(en)
|
2015-06-16 |
2022-09-26 |
Merck Patent GmbH |
Pd-l1 antagonist combination treatments
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
KR20180019725A
(ko)
*
|
2015-06-23 |
2018-02-26 |
메모리얼 슬로안-케터링 캔서 센터 |
신규의 피디 1 면역 조절제
|
|
CA2990360C
(en)
|
2015-06-24 |
2024-02-13 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
|
US10973822B2
(en)
|
2015-07-02 |
2021-04-13 |
Celgene Corporation |
Combination therapy for treatment of hematological cancers and solid tumors
|
|
GB201511790D0
(en)
|
2015-07-06 |
2015-08-19 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
MX383464B
(es)
|
2015-07-13 |
2025-03-14 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
|
|
JP6969848B2
(ja)
|
2015-07-13 |
2021-11-24 |
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド |
プリナブリン組成物
|
|
EP3322731B1
(en)
|
2015-07-14 |
2021-01-13 |
Bristol-Myers Squibb Company |
Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1)
|
|
CA2991628C
(en)
|
2015-07-16 |
2020-04-07 |
Bioxcel Therapeutics, Inc. |
A novel approach for treatment of cancer using immunomodulation
|
|
US10786547B2
(en)
|
2015-07-16 |
2020-09-29 |
Biokine Therapeutics Ltd. |
Compositions, articles of manufacture and methods for treating cancer
|
|
CA2992551A1
(en)
|
2015-07-21 |
2017-01-26 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
CN106699888B
(zh)
*
|
2015-07-28 |
2020-11-06 |
上海昀怡健康科技发展有限公司 |
一种pd-1抗体及其制备方法和应用
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
HRP20211058T8
(hr)
|
2015-07-29 |
2021-11-26 |
Novartis Ag |
Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
|
|
EP3328425B1
(en)
|
2015-07-29 |
2021-08-25 |
Novartis AG |
Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
RU2018105846A
(ru)
|
2015-07-29 |
2019-08-28 |
Новартис Аг |
Комбинация антагониста pd-1 с ингибитором egfr
|
|
HUE068868T2
(hu)
|
2015-07-30 |
2025-02-28 |
Macrogenics Inc |
PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
|
|
BR112018002436A2
(pt)
|
2015-08-04 |
2018-09-18 |
Glaxosmithkline Ip Dev Ltd |
tratamento de combinação de usos de métodos destes
|
|
US20180222989A1
(en)
|
2015-08-04 |
2018-08-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
|
CA2994631A1
(en)
|
2015-08-07 |
2017-02-16 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptide specific for lag-3 and pd-1
|
|
WO2017024465A1
(en)
*
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
EP4458417A3
(en)
*
|
2015-08-11 |
2025-02-19 |
Wuxi Biologics Ireland Limited |
Novel anti-pd-1 antibodies
|
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
KR102222186B1
(ko)
|
2015-08-13 |
2021-03-03 |
머크 샤프 앤드 돔 코포레이션 |
Sting 효능제로서 시클릭 디-뉴클레오티드 화합물
|
|
EP3337826A1
(en)
|
2015-08-20 |
2018-06-27 |
Sutro Biopharma, Inc. |
Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
|
|
KR20180038553A
(ko)
|
2015-08-25 |
2018-04-16 |
아르모 바이오사이언시스 인코포레이티드 |
질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
|
|
JP6791951B2
(ja)
|
2015-08-27 |
2020-11-25 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
肺ガンを患っている患者の生存時間を予測するための方法
|
|
AU2016317915B2
(en)
|
2015-09-01 |
2021-02-18 |
Agenus Inc. |
Anti-PD-1 antibodies and methods of use thereof
|
|
CN117510633A
(zh)
|
2015-09-02 |
2024-02-06 |
伊缪泰普有限公司 |
抗lag-3抗体
|
|
WO2017040930A2
(en)
|
2015-09-03 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
|
US20170114098A1
(en)
|
2015-09-03 |
2017-04-27 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
|
WO2017048702A1
(en)
|
2015-09-14 |
2017-03-23 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
|
|
EP3350314A4
(en)
|
2015-09-18 |
2019-02-06 |
Twist Bioscience Corporation |
OLIGONUCLEIC ACID VARIANT LIBRARIES VARIANT AND SYNTHESIS THEREOF
|
|
KR102794025B1
(ko)
|
2015-09-22 |
2025-04-09 |
트위스트 바이오사이언스 코포레이션 |
핵산 합성을 위한 가요성 기판
|
|
WO2017055484A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for determining the metabolic status of lymphomas
|
|
WO2017055322A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of neutrophils in a tissue sample
|
|
WO2017055327A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of endothelial cells in a tissue sample
|
|
WO2017055325A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of nk cells in a tissue sample
|
|
WO2017055319A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of b cells in a tissue sample
|
|
WO2017055324A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cells of monocytic origin in a tissue sample
|
|
WO2017055326A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
|
WO2017055321A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of fibroblasts in a tissue sample
|
|
WO2017055320A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
|
|
BR112018006237A2
(pt)
|
2015-09-29 |
2018-10-09 |
Celgene Corp |
proteínas de ligação a pd-1 e métodos de uso das mesmas
|
|
US20190054090A1
(en)
|
2015-10-01 |
2019-02-21 |
Gilead Sciences, Inc. |
Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
|
|
US12048753B2
(en)
|
2015-10-01 |
2024-07-30 |
Whitehead Institute For Biomedical Research |
Labeling of antibodies
|
|
ES2895034T3
(es)
|
2015-10-02 |
2022-02-17 |
Hoffmann La Roche |
Anticuerpos anti-PD1 y procedimientos de uso
|
|
WO2017055404A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for pd1 and tim3
|
|
BR112018006817A2
(pt)
*
|
2015-10-08 |
2018-10-23 |
Macrogenics Inc |
método de tratamento do câncer
|
|
WO2017060397A1
(en)
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from melanoma metastases
|
|
US11207393B2
(en)
|
2015-10-16 |
2021-12-28 |
President And Fellows Of Harvard College |
Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
|
|
ES2994611T3
(en)
|
2015-10-19 |
2025-01-27 |
Cg Oncology Inc |
Methods of treating solid or lymphatic tumors by combination therapy
|
|
AU2016342269A1
(en)
|
2015-10-22 |
2018-03-29 |
Jounce Therapeutics, Inc. |
Gene signatures for determining icos expression
|
|
CN105238762A
(zh)
*
|
2015-10-26 |
2016-01-13 |
无锡傲锐东源生物科技有限公司 |
抗pd-1蛋白单克隆抗体杂交瘤细胞及其产生的抗pd-1单克隆抗体和应用
|
|
EP3368092B9
(en)
|
2015-10-29 |
2020-07-29 |
Novartis AG |
Antibody conjugates comprising toll-like receptor agonist
|
|
CN106632674B
(zh)
*
|
2015-10-30 |
2018-11-16 |
泽达生物医药有限公司 |
一种抗pd-1单克隆抗体、其药物组合物及其用途
|
|
US10273281B2
(en)
|
2015-11-02 |
2019-04-30 |
Five Prime Therapeutics, Inc. |
CD80 extracellular domain polypeptides and their use in cancer treatment
|
|
PE20181326A1
(es)
|
2015-11-03 |
2018-08-20 |
Janssen Biotech Inc |
Anticuerpos que se unen especificamente a pd-1 y sus usos
|
|
WO2017077382A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
|
SMT202500282T1
(it)
|
2015-11-18 |
2025-09-12 |
Bristol Myers Squibb Co |
Trattamento del cancro del polmone utilizzando una combinazione di un anticorpo anti-pd-1 e di un anticorpo anti-ctla-4
|
|
MX2018006181A
(es)
|
2015-11-23 |
2018-09-24 |
Five Prime Therapeutics Inc |
Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer.
|
|
CN108883173B
(zh)
|
2015-12-02 |
2022-09-06 |
阿吉纳斯公司 |
抗体和其使用方法
|
|
CN107849084B
(zh)
|
2015-12-03 |
2021-09-14 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为sting调节剂的环状嘌呤二核苷酸
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
CN105837692A
(zh)
*
|
2015-12-10 |
2016-08-10 |
苏州佰通生物科技有限公司 |
一种阻断免疫检测点的嵌合抗原受体及其应用
|
|
IL260021B
(en)
|
2015-12-14 |
2022-09-01 |
Macrogenics Inc |
Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
|
|
WO2017106062A1
(en)
|
2015-12-15 |
2017-06-22 |
Merck Sharp & Dohme Corp. |
Novel compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
ES2979210T3
(es)
|
2015-12-15 |
2024-09-24 |
Oncoc4 Inc |
Anticuerpos monoclonales anti-CTLA4 humano quiméricos y humanizados y usos de los mismos
|
|
ES2986067T3
(es)
|
2015-12-17 |
2024-11-08 |
Novartis Ag |
Moléculas de anticuerpos frente a PD-1 y usos de las mismas
|
|
MA44075A
(fr)
|
2015-12-17 |
2021-05-19 |
Incyte Corp |
Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
|
|
US10392442B2
(en)
|
2015-12-17 |
2019-08-27 |
Bristol-Myers Squibb Company |
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
|
|
RU2018126297A
(ru)
|
2015-12-18 |
2020-01-22 |
Новартис Аг |
Антитела, нацеленные на cd32b, и способы их применения
|
|
AU2016379372A1
(en)
|
2015-12-22 |
2018-08-02 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
EP4643874A3
(en)
|
2015-12-22 |
2026-02-11 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
LT3394103T
(lt)
|
2015-12-22 |
2023-09-11 |
Regeneron Pharmaceuticals, Inc. |
Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti
|
|
CN105669864B
(zh)
|
2015-12-23 |
2018-10-16 |
杭州尚健生物技术有限公司 |
抗人程序性死亡受体1抗体及其制备方法和用途
|
|
EP3400443B1
(en)
|
2016-01-04 |
2020-09-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
|
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
CN106943597A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
CN106943596A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
SG11201805779TA
(en)
|
2016-01-08 |
2018-08-30 |
Celgene Corp |
Antiproliferative compounds, and their pharmaceutical compositions and uses
|
|
CN108601777B
(zh)
|
2016-01-08 |
2021-08-03 |
细胞基因公司 |
2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的制剂
|
|
WO2017120415A1
(en)
|
2016-01-08 |
2017-07-13 |
Celgene Corporation |
Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
|
|
WO2017122130A1
(en)
|
2016-01-11 |
2017-07-20 |
Novartis Ag |
Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
|
|
US11214617B2
(en)
|
2016-01-22 |
2022-01-04 |
MabQuest SA |
Immunological reagents
|
|
ES2924775T3
(es)
|
2016-01-28 |
2022-10-10 |
Inst Nat Sante Rech Med |
Métodos y composición farmacéutica para el tratamiento del cáncer
|
|
JP6902040B2
(ja)
|
2016-01-28 |
2021-07-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
免疫チェックポイント阻害剤の効力を増強する方法
|
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
|
WO2017133175A1
(en)
*
|
2016-02-04 |
2017-08-10 |
Nanjing Legend Biotech Co., Ltd. |
Engineered mammalian cells for cancer therapy
|
|
CN116769054A
(zh)
|
2016-02-05 |
2023-09-19 |
奥里尼斯生物科学私人有限公司 |
双特异性信号传导剂及其用途
|
|
US11752238B2
(en)
|
2016-02-06 |
2023-09-12 |
President And Fellows Of Harvard College |
Recapitulating the hematopoietic niche to reconstitute immunity
|
|
KR20180105685A
(ko)
|
2016-02-08 |
2018-09-28 |
비욘드스프링 파마수티컬스, 인코포레이티드. |
투카레솔 또는 이의 유사체를 함유하는 조성물
|
|
WO2017137830A1
(en)
|
2016-02-12 |
2017-08-17 |
Janssen Pharmaceutica Nv |
Anti-vista (b7h5) antibodies
|
|
AU2017219254B2
(en)
|
2016-02-17 |
2019-12-12 |
Novartis Ag |
TGFbeta 2 antibodies
|
|
US20200270265A1
(en)
|
2016-02-19 |
2020-08-27 |
Novartis Ag |
Tetracyclic pyridone compounds as antivirals
|
|
MX2018010295A
(es)
|
2016-02-26 |
2019-06-06 |
Inst Nat Sante Rech Med |
Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
|
|
CA3015913A1
(en)
|
2016-02-29 |
2017-09-08 |
Foundation Medicine, Inc. |
Methods of treating cancer
|
|
JP6821693B2
(ja)
|
2016-02-29 |
2021-01-27 |
ジェネンテック， インコーポレイテッド |
がんのための治療方法及び診断方法
|
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
KR20180118175A
(ko)
|
2016-03-04 |
2018-10-30 |
노파르티스 아게 |
다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
|
|
WO2017155981A1
(en)
|
2016-03-07 |
2017-09-14 |
Massachusetts Institute Of Technology |
Protein-chaperoned t-cell vaccines
|
|
WO2017156349A1
(en)
|
2016-03-10 |
2017-09-14 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
|
JP7137474B2
(ja)
|
2016-03-15 |
2022-09-14 |
メルサナ セラピューティクス，インコーポレイティド |
ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法
|
|
WO2017160975A1
(en)
*
|
2016-03-16 |
2017-09-21 |
Bristol-Myers Squibb Company |
Methods of diagnosing and treating lupus
|
|
WO2017165412A2
(en)
|
2016-03-21 |
2017-09-28 |
Dana-Farber Cancer Institute, Inc. |
T-cell exhaustion state-specific gene expression regulators and uses thereof
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
JP7069032B2
(ja)
|
2016-03-24 |
2022-05-17 |
ミレニアム ファーマシューティカルズ， インコーポレイテッド |
がん免疫治療における胃腸の免疫関連有害事象の治療方法
|
|
US9988416B2
(en)
|
2016-03-24 |
2018-06-05 |
Novartis Ag |
Alkynyl nucleoside analogs as inhibitors of human rhinovirus
|
|
WO2017165742A1
(en)
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
|
|
WO2017173334A1
(en)
|
2016-04-01 |
2017-10-05 |
Checkmate Pharmaceuticals, Inc. |
Fc receptor-mediated drug delivery
|
|
CN107286242B
(zh)
*
|
2016-04-01 |
2019-03-22 |
中山康方生物医药有限公司 |
抗pd-1的单克隆抗体
|
|
EP3225253A1
(en)
|
2016-04-01 |
2017-10-04 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
|
|
US10358463B2
(en)
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US11209441B2
(en)
|
2016-04-05 |
2021-12-28 |
Bristol-Myers Squibb Company |
Cytokine profiling analysis
|
|
JP2019510802A
(ja)
|
2016-04-07 |
2019-04-18 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
タンパク質調節物質として有用な複素環アミド
|
|
PT3440076T
(pt)
|
2016-04-07 |
2022-07-29 |
Glaxosmithkline Ip Dev Ltd |
Amidas heterocíclicas úteis como modeladores de proteína
|
|
KR20180133442A
(ko)
|
2016-04-13 |
2018-12-14 |
비비아 바이오테크 에스.엘. |
생체외 bite 활성화된 t 세포
|
|
BR112018070948A2
(pt)
|
2016-04-13 |
2019-01-29 |
Orimabs Ltd. |
anticorpos anti-psma e utilização dos mesmos
|
|
KR20230119259A
(ko)
|
2016-04-15 |
2023-08-16 |
이뮤넥스트, 인크. |
항-인간 vista 항체 및 이의 용도
|
|
WO2017188350A1
(ja)
|
2016-04-28 |
2017-11-02 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍の成長を抑制する方法
|
|
CN109640959B
(zh)
|
2016-04-29 |
2023-03-17 |
西奈山伊坎医学院 |
靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
|
|
US20190298824A1
(en)
|
2016-05-04 |
2019-10-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv |
Albumin-binding immunomodulatory compositions and methods of use thereof
|
|
KR20190003699A
(ko)
|
2016-05-05 |
2019-01-09 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
제스트 인핸서 상동체 2 억제제
|
|
AR108377A1
(es)
|
2016-05-06 |
2018-08-15 |
Medimmune Llc |
Proteínas de unión biespecíficas y sus usos
|
|
TWI910495B
(zh)
|
2016-05-13 |
2026-01-01 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
|
WO2017194783A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Targeted mutant interferon-beta and uses thereof
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
EP3455245A2
(en)
|
2016-05-13 |
2019-03-20 |
Orionis Biosciences NV |
Therapeutic targeting of non-cellular structures
|
|
RS61510B1
(sr)
|
2016-05-18 |
2021-03-31 |
Boehringer Ingelheim Int |
Anti pd-1 i anti-lag3 antitela za lečenje kancera
|
|
CN105968200B
(zh)
|
2016-05-20 |
2019-03-15 |
瑞阳(苏州)生物科技有限公司 |
抗人pd-l1人源化单克隆抗体及其应用
|
|
JP7194022B2
(ja)
|
2016-05-20 |
2022-12-21 |
イーライ リリー アンド カンパニー |
Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
EP3493844A4
(en)
|
2016-05-20 |
2021-03-24 |
Harpoon Therapeutics Inc. |
SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
|
|
WO2017202962A1
(en)
|
2016-05-24 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
|
|
CN106008714B
(zh)
|
2016-05-24 |
2019-03-15 |
瑞阳(苏州)生物科技有限公司 |
抗人pd-1人源化单克隆抗体及其应用
|
|
CN116376812A
(zh)
|
2016-05-25 |
2023-07-04 |
国家医疗保健研究所 |
治疗癌症的方法和组合物
|
|
EP3464360B1
(en)
|
2016-05-27 |
2025-11-12 |
Agenus Inc. |
Anti-tim-3 antibodies and methods of use thereof
|
|
EP4253419A3
(en)
|
2016-06-02 |
2024-05-22 |
Ultimovacs ASA |
A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
|
|
ES2954139T3
(es)
|
2016-06-02 |
2023-11-20 |
Bristol Myers Squibb Co |
Bloqueo de PD-1 con nivolumab en el linfoma de Hodgkin refractario
|
|
SG10202101062YA
(en)
*
|
2016-06-02 |
2021-03-30 |
Bristol Myers Squibb Co |
Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
|
|
CN109476753A
(zh)
|
2016-06-03 |
2019-03-15 |
百时美施贵宝公司 |
用于治疗肿瘤的方法的抗-pd-1抗体
|
|
JP2019517512A
(ja)
|
2016-06-03 |
2019-06-24 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用
|
|
CN109475634A
(zh)
|
2016-06-03 |
2019-03-15 |
百时美施贵宝公司 |
用于治疗复发性小细胞肺癌的方法的抗-pd-1抗体
|
|
JP7025416B2
(ja)
|
2016-06-06 |
2022-02-24 |
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド |
好中球減少症を低減させるための組成物および方法
|
|
CA3026982A1
(en)
|
2016-06-08 |
2017-12-14 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
|
AU2017279027A1
(en)
|
2016-06-08 |
2018-12-20 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical Compounds
|
|
CN109715196A
(zh)
|
2016-06-13 |
2019-05-03 |
转矩医疗股份有限公司 |
用于促进免疫细胞功能的组合物和方法
|
|
JP7010854B2
(ja)
*
|
2016-06-14 |
2022-01-26 |
ゼンコア インコーポレイテッド |
二重特異性チェックポイント阻害剤抗体
|
|
JP6941630B2
(ja)
|
2016-06-14 |
2021-09-29 |
ノバルティス アーゲー |
抗菌剤としての（ｒ）−４（５−（シクロプロピルエチニル）イソオキサゾール−３−イル）−ｎ−ヒドロキシ−２−メチル−２−（メチルスルホニル）ブタンアミドの結晶形
|
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
HUE060256T2
(hu)
|
2016-06-20 |
2023-02-28 |
Incyte Corp |
Heterociklusos vegyületek mint immunmodulátorok
|
|
SG11201811237WA
(en)
|
2016-06-24 |
2019-01-30 |
Infinity Pharmaceuticals Inc |
Combination therapies
|
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
|
WO2018011166A2
(en)
|
2016-07-12 |
2018-01-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
|
EP4302834A3
(en)
|
2016-07-12 |
2024-07-17 |
Revolution Medicines, Inc. |
2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
|
|
CN109789092A
(zh)
|
2016-07-13 |
2019-05-21 |
哈佛学院院长等 |
抗原呈递细胞模拟支架及其制备和使用方法
|
|
US20190241573A1
(en)
|
2016-07-20 |
2019-08-08 |
Glaxosmithkline Intellectual Property Development Limited |
Isoquinoline derivatives as perk inhibitors
|
|
EP3487878A4
(en)
|
2016-07-20 |
2020-03-25 |
University of Utah Research Foundation |
CD229-CAR-T CELLS AND METHOD FOR USE THEREOF
|
|
AU2017302668B9
(en)
|
2016-07-28 |
2023-06-22 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and PD-1 inhibitors
|
|
WO2018022438A1
(en)
|
2016-07-29 |
2018-02-01 |
Eli Lilly And Company |
Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
|
|
US20210369746A1
(en)
|
2016-08-01 |
2021-12-02 |
Molecular Templates, Inc. |
Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
|
|
IL264557B2
(en)
|
2016-08-02 |
2024-01-01 |
Harvard College |
Biological agents for regulating immune responses
|
|
US12084495B2
(en)
|
2016-08-03 |
2024-09-10 |
Nextcure, Inc. |
Compositions and methods for modulating LAIR signal transduction
|
|
EP3494140A1
(en)
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos and anti-pd-1 antibody combination therapy
|
|
WO2018027524A1
(en)
|
2016-08-09 |
2018-02-15 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibody formulation
|
|
WO2018029336A1
(en)
|
2016-08-12 |
2018-02-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
|
|
EP3500672A4
(en)
|
2016-08-22 |
2020-05-20 |
Twist Bioscience Corporation |
DE NOVO SYNTHETIZED NUCLEIC ACID LIBRARIES
|
|
EP3500294A4
(en)
|
2016-08-22 |
2020-07-29 |
Arbutus Biopharma Corporation |
ANTI-PD-1 ANTIBODIES, OR THEIR FRAGMENTS, FOR THE TREATMENT OF HEPATITIS B
|
|
CN106977602B
(zh)
*
|
2016-08-23 |
2018-09-25 |
中山康方生物医药有限公司 |
一种抗pd1单克隆抗体、其药物组合物及其用途
|
|
CN106967172B
(zh)
|
2016-08-23 |
2019-01-08 |
康方药业有限公司 |
抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
|
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
|
CN112481217A
(zh)
|
2016-09-01 |
2021-03-12 |
嵌合体生物工程公司 |
Gold优化的car t-细胞
|
|
US11583516B2
(en)
|
2016-09-07 |
2023-02-21 |
Trustees Of Tufts College |
Dash inhibitors, and uses related thereto
|
|
WO2018049263A1
(en)
|
2016-09-09 |
2018-03-15 |
Tg Therapeutics, Inc. |
Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
|
|
TW201811788A
(zh)
|
2016-09-09 |
2018-04-01 |
瑞士商諾華公司 |
作為抗病毒劑之多環吡啶酮化合物
|
|
US20190218294A1
(en)
|
2016-09-09 |
2019-07-18 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
|
|
WO2018046738A1
(en)
|
2016-09-12 |
2018-03-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from cancer
|
|
WO2018046736A1
(en)
|
2016-09-12 |
2018-03-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from cancer
|
|
MY192158A
(en)
|
2016-09-14 |
2022-08-03 |
Abbvie Biotherapeutics Inc |
Anti-pd-1 antibodies and their uses
|
|
US11090391B2
(en)
|
2016-09-16 |
2021-08-17 |
The Johns Hopkins University |
Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery
|
|
MX2019002867A
(es)
|
2016-09-19 |
2019-11-12 |
Celgene Corp |
Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
|
|
JP2019534859A
(ja)
|
2016-09-19 |
2019-12-05 |
セルジーン コーポレイション |
Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
|
|
EP4360714A3
(en)
|
2016-09-21 |
2024-07-24 |
Nextcure, Inc. |
Antibodies for siglec-15 and methods of use thereof
|
|
DK3515478T3
(da)
|
2016-09-21 |
2024-05-21 |
Nextcure Inc |
Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
|
|
US10417457B2
(en)
|
2016-09-21 |
2019-09-17 |
Twist Bioscience Corporation |
Nucleic acid based data storage
|
|
WO2018057585A1
(en)
|
2016-09-21 |
2018-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
|
|
WO2018055080A1
(en)
|
2016-09-22 |
2018-03-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
|
|
JP7274413B2
(ja)
|
2016-09-23 |
2023-05-16 |
マレンゴ・セラピューティクス，インコーポレーテッド |
ラムダ及びカッパ軽鎖を含む多重特異性抗体分子
|
|
JOP20190061A1
(ar)
|
2016-09-28 |
2019-03-26 |
Novartis Ag |
مثبطات بيتا-لاكتاماز
|
|
PT3523287T
(pt)
|
2016-10-04 |
2021-10-06 |
Merck Sharp & Dohme |
Compostos de benzo[b]tiofeno como agonistas de sting
|
|
KR20190062515A
(ko)
|
2016-10-06 |
2019-06-05 |
화이자 인코포레이티드 |
암의 치료를 위한 아벨루맙의 투약 용법
|
|
BR112019006781A2
(pt)
|
2016-10-07 |
2019-07-30 |
Novartis Ag |
receptores de antígeno quiméricos para o tratamento de câncer
|
|
AU2017342176A1
(en)
|
2016-10-10 |
2019-05-02 |
The National Institute for Biotechnology in the Negev Ltd. |
Non-cytotoxic modified cells and use thereof
|
|
JP7066696B2
(ja)
|
2016-10-11 |
2022-05-13 |
アジェナス インコーポレイテッド |
抗ｌａｇ－３抗体及びその使用方法
|
|
WO2018071576A1
(en)
|
2016-10-14 |
2018-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of tumors by inhibition of cd300f
|
|
WO2018071792A1
(en)
|
2016-10-14 |
2018-04-19 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
|
|
WO2018073753A1
(en)
|
2016-10-18 |
2018-04-26 |
Novartis Ag |
Fused tetracyclic pyridone compounds as antivirals
|
|
WO2018075447A1
(en)
|
2016-10-19 |
2018-04-26 |
The Trustees Of Columbia University In The City Of New York |
Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
|
|
WO2018077893A1
(en)
|
2016-10-24 |
2018-05-03 |
Orionis Biosciences Nv |
Targeted mutant interferon-gamma and uses thereof
|
|
JP7258747B2
(ja)
|
2016-10-28 |
2023-04-17 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗ｐｄ－１抗体を用いた尿路上皮癌の処置方法
|
|
JP2019533458A
(ja)
|
2016-11-01 |
2019-11-21 |
アナプティスバイオ インコーポレイティッド |
プログラム死１（ｐｄ−１）に対する抗体
|
|
WO2018083087A2
(en)
|
2016-11-02 |
2018-05-11 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Binding proteins
|
|
JP7267914B2
(ja)
|
2016-11-02 |
2023-05-02 |
エンクマフ エスアーエールエル |
Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
|
|
MY200695A
(en)
|
2016-11-03 |
2024-01-11 |
Bristol Myers Squibb Co |
Activatable anti-ctla-4 antibodies and uses thereof
|
|
US10342785B2
(en)
|
2016-11-04 |
2019-07-09 |
Askat Inc. |
Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
|
|
IT201600111877A1
(it)
*
|
2016-11-07 |
2018-05-07 |
Biouniversa Srl |
Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
|
|
KR102526034B1
(ko)
|
2016-11-07 |
2023-04-25 |
브리스톨-마이어스 스큅 컴퍼니 |
면역조정제
|
|
US20190345500A1
(en)
|
2016-11-14 |
2019-11-14 |
|Nserm (Institut National De La Santé Et De La Recherche Médicale) |
Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
|
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
US20190365788A1
(en)
|
2016-11-21 |
2019-12-05 |
Idenix Pharmaceuticals Llc |
Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
TW201825119A
(zh)
|
2016-11-30 |
2018-07-16 |
日商協和醱酵麒麟有限公司 |
使用抗ccr4抗體及抗pd-1抗體治療癌症之方法
|
|
KR20190090823A
(ko)
|
2016-12-01 |
2019-08-02 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
조합 요법
|
|
US20190343803A1
(en)
|
2016-12-01 |
2019-11-14 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
CN110248678A
(zh)
|
2016-12-03 |
2019-09-17 |
朱诺治疗学股份有限公司 |
调节car-t细胞的方法
|
|
DK3551660T5
(da)
|
2016-12-07 |
2024-09-02 |
Agenus Inc |
Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
|
|
CN110300599B
(zh)
|
2016-12-07 |
2024-07-02 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
MX2019006694A
(es)
|
2016-12-08 |
2019-08-21 |
Lixte Biotechnology Inc |
Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
|
|
JP7101678B2
(ja)
|
2016-12-22 |
2022-07-15 |
インサイト・コーポレイション |
免疫調節剤としての複素環式化合物
|
|
US20180179202A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
CN110869052A
(zh)
|
2016-12-23 |
2020-03-06 |
维图生物制剂公司 |
癌症的治疗
|
|
RU2768404C2
(ru)
*
|
2016-12-23 |
2022-03-24 |
Ремд Биотерапьютикс, Инк. |
Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1)
|
|
WO2018122245A1
(en)
|
2016-12-28 |
2018-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
|
|
WO2018122249A1
(en)
|
2016-12-28 |
2018-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
|
|
WO2018129381A1
(en)
|
2017-01-06 |
2018-07-12 |
Beyondspring Pharmaceuticals, Inc. |
Tubulin binding compounds and therapeutic use thereof
|
|
US11613785B2
(en)
|
2017-01-09 |
2023-03-28 |
Onkosxcel Therapeutics, Llc |
Predictive and diagnostic methods for prostate cancer
|
|
AU2018206481B2
(en)
|
2017-01-09 |
2025-02-27 |
Tesaro, Inc. |
Methods of treating cancer with anti-PD-1 antibodies
|
|
EP3568466A4
(en)
|
2017-01-10 |
2020-07-15 |
The General Hospital Corporation |
TARGETED T CELLS WITH CYTOTOXICITY TO IMMUNOSUPPRESSIVE CELLS
|
|
JP2020503883A
(ja)
|
2017-01-13 |
2020-02-06 |
アジェナス インコーポレイテッド |
Ｎｙ−ｅｓｏ−１に結合するｔ細胞受容体およびその使用方法
|
|
WO2018134279A1
(en)
|
2017-01-18 |
2018-07-26 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptides specific for lag-3 and pd-1
|
|
WO2018134784A1
(en)
|
2017-01-20 |
2018-07-26 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
KR20190110588A
(ko)
|
2017-01-23 |
2019-09-30 |
레볼루션 메디슨즈, 인크. |
알로스테릭 shp2 억제제로서의 피리딘 화합물
|
|
JP7240319B2
(ja)
|
2017-01-23 |
2023-03-15 |
レヴォリューション・メディスンズ，インコーポレイテッド |
アロステリックｓｈｐ２阻害剤としての二環式化合物
|
|
WO2018140671A1
(en)
|
2017-01-27 |
2018-08-02 |
Celgene Corporation |
3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
|
|
BR112019015974A2
(pt)
|
2017-02-01 |
2020-03-31 |
Beyondspring Pharmaceuticals, Inc. |
Método para reduzir neutropenia
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
KR102642385B1
(ko)
|
2017-02-06 |
2024-03-04 |
오리오니스 바이오사이언시스 엔브이 |
표적화된 키메라 단백질 및 이의 용도
|
|
CN110573172A
(zh)
|
2017-02-06 |
2019-12-13 |
奥里尼斯生物科学有限公司 |
靶向的工程化干扰素及其用途
|
|
WO2018146128A1
(en)
|
2017-02-07 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
|
|
WO2018146148A1
(en)
|
2017-02-07 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A method for predicting the response to checkpoint blockade cancer immunotherapy
|
|
HUE057337T2
(hu)
|
2017-02-10 |
2022-05-28 |
Novartis Ag |
1-(4-amino-5-bróm-6-(1H-pirazol-1-il)pirimidin-2-il)-1H-pirazol-4-ol és alkalmazása rák kezelésében
|
|
US20190375847A1
(en)
|
2017-02-15 |
2019-12-12 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
MA47604A
(fr)
|
2017-02-21 |
2020-01-01 |
Regeneron Pharma |
Anticorps anti-pd-1 pour le traitement du cancer du poumon
|
|
EP3585813A1
(en)
*
|
2017-02-22 |
2020-01-01 |
Sutro Biopharma, Inc. |
Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
|
|
EP4556433A3
(en)
|
2017-02-22 |
2025-08-06 |
Twist Bioscience Corporation |
Nucleic acid based data storage
|
|
AU2018224094B2
(en)
|
2017-02-24 |
2025-04-17 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|
|
US20200062735A1
(en)
|
2017-02-27 |
2020-02-27 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors
|
|
US20180271996A1
(en)
|
2017-02-28 |
2018-09-27 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
|
US11161905B2
(en)
|
2017-03-04 |
2021-11-02 |
Xiangtan Tenghua Bioscience |
Recombinant antibodies to programmed death 1 (PD-1) and uses thereof
|
|
WO2018163051A1
(en)
|
2017-03-06 |
2018-09-13 |
Novartis Ag |
Methods of treatment of cancer with reduced ubb expression
|
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
|
US20200150125A1
(en)
|
2017-03-12 |
2020-05-14 |
Yeda Research And Development Co., Ltd. |
Methods of diagnosing and prognosing cancer
|
|
WO2018170169A1
(en)
|
2017-03-15 |
2018-09-20 |
Twist Bioscience Corporation |
Variant libraries of the immunological synapse and synthesis thereof
|
|
EP3596108A4
(en)
|
2017-03-15 |
2020-12-23 |
Pandion Operations, Inc. |
TARGETED IMMUNOTOLERANCE
|
|
AU2018235944B2
(en)
|
2017-03-15 |
2024-01-04 |
Amgen Inc. |
Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
|
|
US20210186982A1
(en)
|
2017-03-24 |
2021-06-24 |
Universite Nice Sophia Antipolis |
Methods and compositions for treating melanoma
|
|
EP3601355A1
(en)
|
2017-03-31 |
2020-02-05 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
CN110709420A
(zh)
|
2017-03-31 |
2020-01-17 |
戊瑞治疗有限公司 |
使用抗gitr抗体的癌症组合疗法
|
|
CN106987631A
(zh)
*
|
2017-04-01 |
2017-07-28 |
武汉赛云博生物科技有限公司 |
一种用于pd‑1/pd‑l1阻断治疗伴随诊断的免疫组测序技术
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
MY201482A
(en)
|
2017-04-03 |
2024-02-26 |
Hoffmann La Roche |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
|
EP4516809A3
(en)
|
2017-04-05 |
2025-09-03 |
F. Hoffmann-La Roche AG |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
KR20240017409A
(ko)
|
2017-04-13 |
2024-02-07 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
|
EP4599893A3
(en)
|
2017-04-14 |
2025-11-05 |
CG Oncology, Inc. |
Cg0070 for treating bcg resistant bladder carcinoma in situ
|
|
WO2018195123A1
(en)
|
2017-04-18 |
2018-10-25 |
Tempest Therapeutics, Inc. |
Bicyclic compounds and their use in the treatment of cancer
|
|
US12460208B2
(en)
|
2017-04-18 |
2025-11-04 |
Parr Biotechnology Co., Ltd. |
Immunomodulatory polynucleotides and uses thereof
|
|
CN108728444A
(zh)
|
2017-04-18 |
2018-11-02 |
长春华普生物技术股份有限公司 |
免疫调节性多核苷酸及其应用
|
|
CN110709422B
(zh)
|
2017-04-19 |
2023-12-26 |
马伦戈治疗公司 |
多特异性分子及其用途
|
|
EP4286009A3
(en)
|
2017-04-21 |
2024-04-03 |
Sillajen, Inc. |
Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
|
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
AR111432A1
(es)
|
2017-04-28 |
2019-07-10 |
Merck Sharp & Dohme |
Biomarcadores para agentes terapéuticos contra el cáncer
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
US20200385472A1
(en)
|
2017-04-28 |
2020-12-10 |
Elstar Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
LT3618863T
(lt)
|
2017-05-01 |
2023-10-10 |
Agenus Inc. |
Anti-tigit antikūnai ir jų panaudojimo būdai
|
|
JP7382232B2
(ja)
|
2017-05-02 |
2023-11-16 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
AR111658A1
(es)
|
2017-05-05 |
2019-08-07 |
Novartis Ag |
2-quinolinonas tricíclicas como agentes antibacteriales
|
|
US11466047B2
(en)
|
2017-05-12 |
2022-10-11 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
|
EP3621994A4
(en)
|
2017-05-12 |
2020-12-30 |
Harpoon Therapeutics, Inc. |
MESOTHELIN BINDING PROTEINS
|
|
CN110869392A
(zh)
|
2017-05-16 |
2020-03-06 |
百时美施贵宝公司 |
用抗gitr激动性抗体治疗癌症
|
|
AR111760A1
(es)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
|
|
MY206158A
(en)
|
2017-05-24 |
2024-12-02 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
US10676516B2
(en)
|
2017-05-24 |
2020-06-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
WO2018215938A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
JP2020522495A
(ja)
|
2017-05-30 |
2020-07-30 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物
|
|
ES2965352T3
(es)
|
2017-05-30 |
2024-04-12 |
Bristol Myers Squibb Co |
Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3)
|
|
CN110678200B
(zh)
|
2017-05-30 |
2024-05-17 |
百时美施贵宝公司 |
包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
|
|
CN111051346A
(zh)
|
2017-05-31 |
2020-04-21 |
斯特库伯株式会社 |
使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
|
|
EP3630836A1
(en)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
JP7273732B2
(ja)
|
2017-05-31 |
2023-05-15 |
ノバルティス アーゲー |
５－ブロモ－２，６－ジ（１ｈ－ピラゾール－１－イル）ピリミジン－４－アミン及び新たな塩の結晶形
|
|
KR20200041834A
(ko)
|
2017-06-01 |
2020-04-22 |
젠코어 인코포레이티드 |
Cd123 및 cd3에 결합하는 이중특이성 항체
|
|
KR20240149982A
(ko)
|
2017-06-01 |
2024-10-15 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체를 사용하여 종양을 치료하는 방법
|
|
WO2018223004A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
|
WO2018222989A1
(en)
|
2017-06-02 |
2018-12-06 |
The Penn State Research Foundation |
Ceramide nanoliposomes, compositions and methods of using for immunotherapy
|
|
AU2018275894B2
(en)
|
2017-06-02 |
2025-04-24 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
|
KR20200026209A
(ko)
|
2017-06-06 |
2020-03-10 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
|
|
WO2018225093A1
(en)
|
2017-06-07 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
|
JP2020522555A
(ja)
|
2017-06-09 |
2020-07-30 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
組み合わせ療法
|
|
ES3000510T3
(en)
|
2017-06-09 |
2025-02-28 |
Providence Health & Services Oregon |
Tumor-infiltrating t-cells for use in the treatment of cancer
|
|
WO2018231872A1
(en)
|
2017-06-12 |
2018-12-20 |
Twist Bioscience Corporation |
Methods for seamless nucleic acid assembly
|
|
WO2018231864A1
(en)
|
2017-06-12 |
2018-12-20 |
Twist Bioscience Corporation |
Methods for seamless nucleic acid assembly
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
JP2020524157A
(ja)
|
2017-06-20 |
2020-08-13 |
アンスティテュート キュリー |
がん併用療法における使用のためのｓｕｖ３９ｈ１ヒストンメチルトランスフェラーゼの阻害剤
|
|
MY204117A
(en)
|
2017-06-22 |
2024-08-08 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
CA3061874A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
|
TWI787284B
(zh)
|
2017-06-22 |
2022-12-21 |
美商西建公司 |
以b型肝炎病毒感染表徵之肝細胞癌之治療
|
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
|
CA3067268A1
(en)
|
2017-06-23 |
2018-12-27 |
Birdie Biopharmaceuticals, Inc. |
Crystalline resiquimod monosulfate anhydrate and its preparation and uses
|
|
EP3642220A1
(en)
|
2017-06-23 |
2020-04-29 |
Bristol-Myers Squibb Company |
Immunomodulators acting as antagonists of pd-1
|
|
WO2019005635A2
(en)
*
|
2017-06-25 |
2019-01-03 |
Systimmune, Inc. |
ANTI-PD-1 ANTIBODIES AND METHODS OF PREPARATION AND USE
|
|
CA3066747A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
|
JP2020526194A
(ja)
|
2017-06-29 |
2020-08-31 |
ジュノー セラピューティクス インコーポレイテッド |
免疫療法薬と関連する毒性を評価するためのマウスモデル
|
|
KR20200020899A
(ko)
|
2017-06-30 |
2020-02-26 |
셀진 코포레이션 |
2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드의 조성물 및 사용 방법
|
|
CN110896634A
(zh)
|
2017-07-03 |
2020-03-20 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为atf4抑制剂用于治疗癌症和其它疾病的2-(4-氯苯氧基)-n-((1-(2-(4-氯苯氧基)乙炔氮杂环丁烷-3-基)甲基)乙酰胺衍生物和相关化合物
|
|
US20210145771A1
(en)
|
2017-07-03 |
2021-05-20 |
Glaxosmithkline Intellectual Property Development Limited |
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
|
|
EP4467143B1
(en)
|
2017-07-10 |
2026-03-11 |
Celgene Corporation |
Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile
|
|
WO2019016174A1
(en)
|
2017-07-18 |
2019-01-24 |
Institut Gustave Roussy |
METHOD FOR ASSESSING RESPONSE TO TARGETING DRUG PD-1 / PDL-1 MEDICINES
|
|
JP2020527572A
(ja)
|
2017-07-20 |
2020-09-10 |
ノバルティス アーゲー |
抗ｌａｇ−３抗体の投薬量レジメンおよびその使用
|
|
WO2019020593A1
(en)
|
2017-07-25 |
2019-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF MONOCYTOPOISIS
|
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
|
JP7274454B2
(ja)
|
2017-07-28 |
2023-05-16 |
ブリストル－マイヤーズ スクイブ カンパニー |
チェックポイント阻害薬のための予測末梢血バイオマーカー
|
|
SG11202000198QA
(en)
|
2017-08-04 |
2020-02-27 |
Genmab As |
Binding agents binding to pd-l1 and cd137 and use thereof
|
|
JP2020530838A
(ja)
|
2017-08-04 |
2020-10-29 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト
|
|
RU2020109328A
(ru)
|
2017-08-04 |
2021-09-06 |
Мерк Шарп И Доум Корп. |
Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака
|
|
BR112020003362A2
(pt)
|
2017-08-28 |
2020-08-18 |
Bristol-Myers Squibb Company |
antagonistas de tim-3 para o tratamento e diagnóstico de cânceres
|
|
CA3073055A1
(en)
|
2017-09-04 |
2019-03-07 |
Agenus Inc. |
T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
|
|
CA3074690A1
(en)
|
2017-09-07 |
2019-03-14 |
Revolution Medicines, Inc. |
Shp2 inhibitor compositions and methods for treating cancer
|
|
MX2020002612A
(es)
|
2017-09-07 |
2020-07-13 |
Univ Res Inst Inc Augusta |
Anticuerpos de la proteina de muerte celular programada 1.
|
|
UY37866A
(es)
|
2017-09-07 |
2019-03-29 |
Glaxosmithkline Ip Dev Ltd |
Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
|
|
US11407837B2
(en)
|
2017-09-11 |
2022-08-09 |
Twist Bioscience Corporation |
GPCR binding proteins and synthesis thereof
|
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
|
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
|
WO2019057744A1
(en)
|
2017-09-19 |
2019-03-28 |
Institut Curie |
AROMATIC HYDROCARBON RECEPTOR AGONIST FOR USE IN ASSOCIATION TREATMENT AGAINST CANCER
|
|
CN109554349B
(zh)
*
|
2017-09-27 |
2022-06-24 |
亘喜生物科技（上海）有限公司 |
Pd-1基因表达沉默的工程化免疫细胞
|
|
US11351163B2
(en)
|
2017-09-29 |
2022-06-07 |
Bristol-Myers Squibb Company |
Compositions and methods of treating cancer
|
|
WO2019061324A1
(en)
|
2017-09-29 |
2019-04-04 |
Curis Inc. |
CRYSTALLINE FORMS OF IMMUNOMODULATORS
|
|
CN111051332B
(zh)
|
2017-10-03 |
2024-09-06 |
百时美施贵宝公司 |
免疫调节剂
|
|
AU2018344902B2
(en)
|
2017-10-05 |
2021-06-03 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (STING) useful in treating HIV
|
|
CA3077337A1
(en)
|
2017-10-05 |
2019-04-11 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (sting)
|
|
CN120248120A
(zh)
*
|
2017-10-10 |
2025-07-04 |
努玛治疗有限公司 |
靶向pdl1的抗体及其使用方法
|
|
EP3694841A1
(en)
|
2017-10-11 |
2020-08-19 |
Aurigene Discovery Technologies Limited |
Crystalline forms of 3-substituted 1,2,4-oxadiazole
|
|
TW201930292A
(zh)
|
2017-10-12 |
2019-08-01 |
美商銳新醫藥公司 |
作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物
|
|
MX2020003915A
(es)
|
2017-10-13 |
2020-10-08 |
Harpoon Therapeutics Inc |
Proteinas trispecificas y metodos de uso.
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
CN111247169A
(zh)
|
2017-10-15 |
2020-06-05 |
百时美施贵宝公司 |
治疗肿瘤的方法
|
|
WO2019077062A1
(en)
|
2017-10-18 |
2019-04-25 |
Vivia Biotech, S.L. |
C-CELLS ACTIVATED BY BIT
|
|
CN111565834B
(zh)
|
2017-10-20 |
2022-08-26 |
特韦斯特生物科学公司 |
用于多核苷酸合成的加热的纳米孔
|
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
|
SG11202003501XA
(en)
|
2017-11-01 |
2020-05-28 |
Juno Therapeutics Inc |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
|
PT3703750T
(pt)
|
2017-11-01 |
2025-01-17 |
Memorial Sloan Kettering Cancer Center |
Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
WO2019089412A1
(en)
|
2017-11-01 |
2019-05-09 |
Merck Sharp & Dohme Corp. |
Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
|
MY206121A
(en)
|
2017-11-03 |
2024-11-29 |
Aurigene Discovery Tech Ltd |
Dual inhibitors of tim-3 and pd-1 pathways
|
|
AU2018360389B2
(en)
|
2017-11-06 |
2024-09-19 |
Aurigene Oncology Limited |
Conjoint therapies for immunomodulation
|
|
WO2019090330A1
(en)
|
2017-11-06 |
2019-05-09 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
JP2021502100A
(ja)
|
2017-11-08 |
2021-01-28 |
ゼンコア インコーポレイテッド |
新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
|
|
US20200353050A1
(en)
|
2017-11-10 |
2020-11-12 |
Armo Biosciences, Inc. |
Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
|
|
KR102718287B1
(ko)
|
2017-11-14 |
2024-10-16 |
머크 샤프 앤드 돔 엘엘씨 |
인돌아민 2,3-디옥시게나제 (ido) 억제제로서의 신규 치환된 비아릴 화합물
|
|
WO2019099294A1
(en)
|
2017-11-14 |
2019-05-23 |
Merck Sharp & Dohme Corp. |
Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
|
CN111655288A
(zh)
|
2017-11-16 |
2020-09-11 |
诺华股份有限公司 |
组合疗法
|
|
CN111712518B
(zh)
|
2017-11-17 |
2025-03-25 |
默沙东有限责任公司 |
对免疫球蛋白样转录物3(ilt3)具有特异性的抗体及其用途
|
|
US20210079015A1
(en)
|
2017-11-17 |
2021-03-18 |
Novartis Ag |
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
|
|
JP7408036B2
(ja)
|
2017-11-24 |
2024-01-05 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ガンを処置するための方法及び組成物
|
|
WO2019104289A1
(en)
|
2017-11-27 |
2019-05-31 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
US20200371091A1
(en)
|
2017-11-30 |
2020-11-26 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
EP3720881A1
(en)
|
2017-12-08 |
2020-10-14 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
US11946094B2
(en)
|
2017-12-10 |
2024-04-02 |
Augusta University Research Institute, Inc. |
Combination therapies and methods of use thereof
|
|
JP7361693B2
(ja)
|
2017-12-15 |
2023-10-16 |
レヴォリューション・メディスンズ，インコーポレイテッド |
アロステリックｓｈｐ２阻害剤としての多環式化合物
|
|
MA51184A
(fr)
|
2017-12-15 |
2020-10-21 |
Juno Therapeutics Inc |
Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
|
|
EP3727401A4
(en)
|
2017-12-20 |
2022-04-06 |
Merck Sharp & Dohme Corp. |
CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
|
|
EP3728266A1
(en)
|
2017-12-20 |
2020-10-28 |
Novartis AG |
Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
|
|
CN111757757A
(zh)
|
2017-12-21 |
2020-10-09 |
梅尔莎纳医疗公司 |
吡咯并苯并二氮呯抗体共轭物
|
|
AU2018395291A1
(en)
|
2017-12-28 |
2020-07-30 |
The General Hospital Corporation |
Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment
|
|
CN109966487B
(zh)
*
|
2017-12-28 |
2023-08-25 |
上海复宏汉霖生物制药有限公司 |
一种包含抗pd-l1单克隆抗体的药物配制剂
|
|
KR102804057B1
(ko)
|
2018-01-04 |
2025-05-07 |
트위스트 바이오사이언스 코포레이션 |
Dna 기반 디지털 정보 저장
|
|
EP3735590A1
(en)
|
2018-01-04 |
2020-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma resistant
|
|
US11324774B2
(en)
|
2018-01-05 |
2022-05-10 |
Augusta University Research Institute, Inc. |
Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
|
|
US12539308B2
(en)
|
2018-01-08 |
2026-02-03 |
The Trustees Of The University Of Pennsylvania |
Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
CA3084370A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
|
EP3740506A1
(en)
|
2018-01-16 |
2020-11-25 |
Bristol-Myers Squibb Company |
Methods of treating cancer with antibodies against tim3
|
|
CA3096287A1
(en)
|
2018-01-22 |
2019-07-25 |
Pascal Biosciences Inc. |
Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
|
|
EP3743076A1
(en)
|
2018-01-22 |
2020-12-02 |
Bristol-Myers Squibb Company |
Compositions and methods of treating cancer
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
CN112566934B
(zh)
|
2018-01-23 |
2024-09-17 |
奈斯科尔公司 |
B7-h4抗体及其使用方法
|
|
KR20200112881A
(ko)
|
2018-01-24 |
2020-10-05 |
비욘드스프링 파마수티컬스, 인코포레이티드. |
플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
|
|
EP3743448A4
(en)
|
2018-01-26 |
2021-11-03 |
Orionis Biosciences, Inc. |
XCR1 BINDING AGENTS AND USES THEREOF
|
|
JP7383620B2
(ja)
|
2018-01-31 |
2023-11-20 |
セルジーン コーポレイション |
養子細胞療法およびチェックポイント阻害剤を使用する併用療法
|
|
AU2019215031C1
(en)
|
2018-01-31 |
2026-02-26 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
WO2019149716A1
(en)
|
2018-01-31 |
2019-08-08 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
|
CN111727044A
(zh)
|
2018-02-05 |
2020-09-29 |
深圳市原力生命科学有限公司 |
用于治疗癌症或炎性疾病的杂二环羧酸
|
|
WO2019157124A1
(en)
|
2018-02-08 |
2019-08-15 |
Bristol-Myers Squibb Company |
Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
|
|
TWI890481B
(zh)
|
2018-02-09 |
2025-07-11 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
NL2020422B1
(en)
|
2018-02-12 |
2019-08-19 |
Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis |
Methods for Predicting Treatment Outcome and/or for Selecting a Subject Suitable for Immune Checkpoint Therapy.
|
|
SG11202007590TA
(en)
|
2018-02-13 |
2020-09-29 |
Merck Sharp & Dohme |
Methods for treating cancer with anti-pd-1 antibodies
|
|
US20200399383A1
(en)
|
2018-02-13 |
2020-12-24 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
WO2019160866A2
(en)
|
2018-02-13 |
2019-08-22 |
Checkmate Pharmaceuticals, Inc. |
Compositions and methods for tumor immunotherapy
|
|
EP3756012A1
(en)
|
2018-02-21 |
2020-12-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
|
|
TWI877770B
(zh)
|
2018-02-27 |
2025-03-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
|
|
EP3759110A1
(en)
|
2018-02-28 |
2021-01-06 |
Novartis AG |
Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
|
|
WO2019169229A1
(en)
|
2018-03-01 |
2019-09-06 |
Nextcure, Inc. |
Klrg1 binding compositions and methods of use thereof
|
|
AR114127A1
(es)
|
2018-03-02 |
2020-07-22 |
Lilly Co Eli |
Anticuerpos agonistas contra pd-1 y usos de estos
|
|
EP3762105A1
(en)
|
2018-03-06 |
2021-01-13 |
Institut Curie |
Inhibitor of setdb1 histone methyltransferase for use in cancer combination therapy
|
|
US20210030703A1
(en)
|
2018-03-12 |
2021-02-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
|
|
EP3765006A4
(en)
|
2018-03-13 |
2022-02-23 |
Merck Sharp & Dohme Corp. |
ARGINASE INHIBITORS AND METHODS OF USE
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
EP3768715A1
(en)
|
2018-03-23 |
2021-01-27 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
|
WO2019185792A1
(en)
|
2018-03-29 |
2019-10-03 |
Philogen S.P.A |
Cancer treatment using immunoconjugates and immune check-point inhibitors
|
|
CN108530537B
(zh)
*
|
2018-03-29 |
2019-07-02 |
中国人民解放军军事科学院军事医学研究院 |
Pd-1/pd-l1信号通路抑制剂
|
|
SMT202500157T1
(it)
|
2018-03-30 |
2025-05-12 |
Incyte Corp |
Composti eterociclici come immunomodulatori
|
|
KR20200139724A
(ko)
|
2018-03-30 |
2020-12-14 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
EP3774765A4
(en)
|
2018-04-03 |
2021-12-29 |
Merck Sharp & Dohme Corp. |
Aza-benzothiophene compounds as sting agonists
|
|
JP7326319B2
(ja)
|
2018-04-03 |
2023-08-15 |
メルク・シャープ・アンド・ドーム・エルエルシー |
Ｓｔｉｎｇアゴニストとしてのベンゾチオフェン類及び関連する化合物
|
|
EP3774903A1
(en)
|
2018-04-04 |
2021-02-17 |
Bristol-Myers Squibb Company |
Anti-cd27 antibodies and uses thereof
|
|
WO2019193541A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
|
|
WO2019193540A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Heteroaryl derivatives of formula (i) as atf4 inhibitors
|
|
BR112020020479A2
(pt)
|
2018-04-09 |
2021-01-12 |
Checkmate Pharmaceuticals |
Empacotamento de oligonucleotídeos em partículas similares a vírus
|
|
BR112020020826A2
(pt)
|
2018-04-12 |
2021-01-19 |
Bristol-Myers Squibb Company |
Terapia de combinação anticâncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
US10968201B2
(en)
|
2018-04-17 |
2021-04-06 |
Tempest Therapeutics, Inc. |
Bicyclic carboxamides and methods of use thereof
|
|
SG11202010163QA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
MA52289A
(fr)
|
2018-04-18 |
2021-02-24 |
Xencor Inc |
Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
|
|
EP3781687A4
(en)
|
2018-04-20 |
2022-02-09 |
Merck Sharp & Dohme Corp. |
NEW RIG-I SUBSTITUTED AGONISTS: COMPOSITIONS AND METHODS THEREOF
|
|
MA52363A
(fr)
|
2018-04-26 |
2021-03-03 |
Agenus Inc |
Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
|
|
WO2019207030A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
US12048745B2
(en)
|
2018-05-01 |
2024-07-30 |
Augusta University Research Institute, Inc. |
Methods for detecting and reversing immune therapy resistance
|
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
HRP20241288T1
(hr)
|
2018-05-04 |
2024-12-06 |
Incyte Corporation |
Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
|
|
AU2019262579B2
(en)
|
2018-05-04 |
2024-09-12 |
Incyte Corporation |
Salts of an FGFR inhibitor
|
|
HUE061503T2
(hu)
|
2018-05-11 |
2023-07-28 |
Incyte Corp |
Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok
|
|
KR20210010896A
(ko)
|
2018-05-14 |
2021-01-28 |
이뮤노코어 리미티드 |
이기능성 결합 폴리펩타이드
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
EP3810610A1
(en)
|
2018-05-18 |
2021-04-28 |
Incyte Corporation |
Fused pyrimidine derivatives as a2a / a2b inhibitors
|
|
CA3100739A1
(en)
|
2018-05-18 |
2019-11-21 |
Twist Bioscience Corporation |
Polynucleotides, reagents, and methods for nucleic acid hybridization
|
|
KR102718800B1
(ko)
|
2018-05-23 |
2024-10-18 |
셀진 코포레이션 |
다발성 골수종의 치료 및 4-(4-(4-(((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-4-일)옥시)메틸)벤질)피페라진-1-일)-3-플루오로벤조니트릴에 대한 바이오마커의 용도
|
|
PL3796912T3
(pl)
|
2018-05-23 |
2023-09-11 |
Celgene Corporation |
Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
WO2019232319A1
(en)
|
2018-05-31 |
2019-12-05 |
Peloton Therapeutics, Inc. |
Compositions and methods for inhibiting cd73
|
|
WO2019231870A1
(en)
|
2018-05-31 |
2019-12-05 |
Merck Sharp & Dohme Corp. |
Novel substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
EP3801766A1
(en)
|
2018-05-31 |
2021-04-14 |
Novartis AG |
Hepatitis b antibodies
|
|
KR102870868B1
(ko)
|
2018-06-01 |
2025-10-15 |
노파르티스 아게 |
Bcma에 대한 결합 분자 및 이의 용도
|
|
EP3801617A1
(en)
|
2018-06-01 |
2021-04-14 |
Novartis Ag |
Dosing of a bispecific antibody that bind cd123 and cd3
|
|
EP3802599B1
(en)
|
2018-06-03 |
2023-12-20 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
TWI890660B
(zh)
|
2018-06-13 |
2025-07-21 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
|
KR20210035805A
(ko)
|
2018-06-15 |
2021-04-01 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
|
|
WO2019245817A1
(en)
|
2018-06-19 |
2019-12-26 |
Armo Biosciences, Inc. |
Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
|
|
US12448448B2
(en)
|
2018-06-20 |
2025-10-21 |
Incyte Corporation |
Anti-PD-1 antibodies and uses thereof
|
|
WO2019245890A1
(en)
|
2018-06-20 |
2019-12-26 |
Merck Sharp & Dohme Corp. |
Arginase inhibitors and methods of use
|
|
TW202504917A
(zh)
|
2018-06-21 |
2025-02-01 |
美商再生元醫藥公司 |
用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法
|
|
WO2020005068A2
(en)
|
2018-06-29 |
2020-01-02 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Gene signatures and method for predicting response to pd-1 antagonists and ctla-4 antagonists, and combination thereof
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
WO2020010284A1
(en)
*
|
2018-07-04 |
2020-01-09 |
Cytoimmune Therapeutics, LLC |
Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1
|
|
WO2020010197A1
(en)
|
2018-07-05 |
2020-01-09 |
Incyte Corporation |
Fused pyrazine derivatives as a2a / a2b inhibitors
|
|
JP2021529814A
(ja)
|
2018-07-09 |
2021-11-04 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
化学化合物
|
|
BR122022012697B1
(pt)
|
2018-07-10 |
2023-04-04 |
Novartis Ag |
Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
US20210277135A1
(en)
|
2018-07-13 |
2021-09-09 |
Bristol-Myers Squibb Company |
Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
|
|
US12258407B2
(en)
|
2018-07-19 |
2025-03-25 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Anti-PD-1 antibodies, dosages and uses thereof
|
|
US20210301020A1
(en)
|
2018-07-24 |
2021-09-30 |
Amgen Inc. |
Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
|
|
JP2021531306A
(ja)
|
2018-07-25 |
2021-11-18 |
アドバンスド アクセラレーター アプリケーションズ エスエー |
神経内分泌腫瘍の処置の方法
|
|
WO2020021061A1
(en)
|
2018-07-26 |
2020-01-30 |
Pieris Pharmaceuticals Gmbh |
Humanized anti-pd-1 antibodies and uses thereof
|
|
CN112739371A
(zh)
|
2018-07-26 |
2021-04-30 |
百时美施贵宝公司 |
用于治疗癌症的lag-3组合疗法
|
|
CN112703011A
(zh)
|
2018-08-06 |
2021-04-23 |
国家医疗保健研究所 |
用于治疗癌症的方法和组合物
|
|
WO2020030571A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
|
|
WO2020031107A1
(en)
|
2018-08-08 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
|
EP3833762A4
(en)
|
2018-08-09 |
2022-09-28 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
|
WO2020037215A1
(en)
|
2018-08-17 |
2020-02-20 |
Icahn School Of Medicine At Mount Sinai |
Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
|
|
US20210246219A1
(en)
|
2018-08-27 |
2021-08-12 |
Pieris Pharmaceuticals Gmbh |
Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
|
|
WO2020044206A1
(en)
|
2018-08-29 |
2020-03-05 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors for use in the treatment cancer
|
|
CN120365435A
(zh)
|
2018-08-30 |
2025-07-25 |
免疫生物公司 |
单链嵌合多肽和多链嵌合多肽以及其用途
|
|
CN112996805A
(zh)
|
2018-08-30 |
2021-06-18 |
Hcw生物科技公司 |
多链嵌合多肽和其用途
|
|
EP3843788A1
(en)
|
2018-08-30 |
2021-07-07 |
HCW Biologics, Inc. |
Single-chain chimeric polypeptides and uses thereof
|
|
WO2020044252A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Dosage regimes for anti-m-csf antibodies and uses thereof
|
|
US20210340279A1
(en)
|
2018-08-31 |
2021-11-04 |
Yale University |
Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
|
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
|
WO2020049534A1
(en)
|
2018-09-07 |
2020-03-12 |
Novartis Ag |
Sting agonist and combination therapy thereof for the treatment of cancer
|
|
JP7654539B2
(ja)
*
|
2018-09-07 |
2025-04-01 |
ファイザー・インク |
抗αｖβ８抗体、組成物及びその使用
|
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
|
CN113164466B
(zh)
|
2018-09-11 |
2025-07-08 |
柯瑞斯公司 |
使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗
|
|
CA3112326A1
(en)
|
2018-09-12 |
2020-03-19 |
Novartis Ag |
Antiviral pyridopyrazinedione compounds
|
|
AU2019337547A1
(en)
|
2018-09-13 |
2021-03-18 |
Merck Sharp & Dohme Llc |
Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
|
|
EP3853251A1
(en)
|
2018-09-19 |
2021-07-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
|
WO2020061129A1
(en)
|
2018-09-19 |
2020-03-26 |
President And Fellows Of Harvard College |
Compositions and methods for labeling and modulation of cells in vitro and in vivo
|
|
EP3853247A2
(en)
|
2018-09-19 |
2021-07-28 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant cd80 fusion proteins and related constructs
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
US10815311B2
(en)
|
2018-09-25 |
2020-10-27 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
|
CN113164777B
(zh)
|
2018-09-27 |
2024-12-13 |
马伦戈治疗公司 |
Csf1r/ccr2多特异性抗体
|
|
WO2020069405A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
|
WO2020069409A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
IL305106B2
(en)
|
2018-09-29 |
2025-08-01 |
Novartis Ag |
Process of manufacture of a compound for inhibiting the activity of shp2
|
|
EP3860578A1
(en)
|
2018-10-01 |
2021-08-11 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of inhibitors of stress granule formation for targeting the regulation of immune responses
|
|
AU2019355971B2
(en)
|
2018-10-03 |
2025-05-08 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
|
JP2022512642A
(ja)
|
2018-10-09 |
2022-02-07 |
ブリストル－マイヤーズ スクイブ カンパニー |
がんを治療するための抗ＭｅｒＴＫ抗体
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
AU2019359475A1
(en)
|
2018-10-12 |
2021-05-20 |
Xencor, Inc. |
PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof
|
|
JP2022504905A
(ja)
|
2018-10-16 |
2022-01-13 |
ノバルティス アーゲー |
標的化療法に対する応答を予測するためのバイオマーカーとしての単独の又は免疫マーカーと組み合わせた腫瘍突然変異負荷
|
|
JP7542529B2
(ja)
|
2018-10-17 |
2024-08-30 |
バイオラインアールエックス・リミテッド |
転移性膵臓腺癌の処置
|
|
WO2020081381A1
(en)
|
2018-10-17 |
2020-04-23 |
Merck Sharp & Dohme Corp. |
Novel arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
CN112955462B
(zh)
|
2018-10-18 |
2024-05-07 |
国家医疗保健研究所 |
用于治疗实体瘤的βIG-H3拮抗剂和免疫检查点抑制剂的组合
|
|
WO2020081408A1
(en)
|
2018-10-18 |
2020-04-23 |
Merck Sharp & Dohme Corp. |
Formulations of anti-rsv antibodies and methods of use thereof
|
|
LT4445958T
(lt)
|
2018-10-19 |
2025-12-10 |
Bristol-Myers Squibb Company |
Kompleksinė terapija, skirta melanomai gydyti
|
|
BR112021007517A2
(pt)
|
2018-10-22 |
2021-10-26 |
Glaxosmithkline Intellectual Property Development Limited |
Dosagem
|
|
WO2020086724A1
(en)
|
2018-10-23 |
2020-04-30 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
CN113365664A
(zh)
|
2018-10-29 |
2021-09-07 |
梅尔莎纳医疗公司 |
具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
|
|
MX2021004928A
(es)
|
2018-10-31 |
2021-06-08 |
Merck Sharp & Dohme Llc |
Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
|
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
EP3873464B1
(en)
|
2018-11-01 |
2025-07-30 |
Merck Sharp & Dohme LLC |
Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
MA54078A
(fr)
|
2018-11-01 |
2021-09-15 |
Juno Therapeutics Inc |
Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
|
|
EP3873937A2
(en)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
|
|
WO2020096871A1
(en)
|
2018-11-06 |
2020-05-14 |
Merck Sharp & Dohme Corp. |
Novel substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
EP3876990A4
(en)
|
2018-11-07 |
2023-09-06 |
Merck Sharp & Dohme LLC |
CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
|
|
US12410225B2
(en)
|
2018-11-08 |
2025-09-09 |
Orionis Biosciences, Inc |
Modulation of dendritic cell lineages
|
|
KR20210119380A
(ko)
|
2018-11-09 |
2021-10-05 |
피어리언 바이오사이언스즈, 엘엘씨 |
종양 미세환경의 조성을 결정하기 위한 방법 및 조성물
|
|
SI3880186T1
(sl)
|
2018-11-14 |
2024-07-31 |
Regeneron Pharmaceuticals, Inc., |
Intralezijska uporaba zaviralcev PD-1 za zdravljenje kožnega raka
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
AU2019379179A1
(en)
|
2018-11-16 |
2021-06-10 |
Arqule, Inc. |
Pharmaceutical combination for treatment of cancer
|
|
IL283218B2
(en)
|
2018-11-16 |
2025-11-01 |
Juno Therapeutics Inc |
Dosing methods of engineered T cells for the treatment of malignant B cells
|
|
CN113316590B
(zh)
|
2018-11-16 |
2025-02-28 |
百时美施贵宝公司 |
抗nkg2a抗体及其用途
|
|
CN113365650A
(zh)
|
2018-11-16 |
2021-09-07 |
新免疫技术有限公司 |
用il-7蛋白和免疫检查点抑制剂的组合治疗肿瘤的方法
|
|
US20230183379A1
(en)
|
2018-11-20 |
2023-06-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bispecific antibody targeting transferrin receptor 1 and soluble antigen
|
|
US12414952B2
(en)
|
2018-11-20 |
2025-09-16 |
Merck Sharp & Dohme Llc |
Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
|
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
|
AU2019383948A1
(en)
|
2018-11-20 |
2021-05-20 |
Merck Sharp & Dohme Llc |
Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
|
|
CN113453678A
(zh)
|
2018-11-26 |
2021-09-28 |
德彪药业国际股份公司 |
Hiv感染的联合治疗
|
|
WO2020109355A1
(en)
|
2018-11-28 |
2020-06-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kit for assaying lytic potential of immune effector cells
|
|
EP3886845B1
(en)
|
2018-11-28 |
2024-09-04 |
Merck Sharp & Dohme LLC |
Novel substituted piperazine amide compounds as indoleamine 2, 3-dioxygenase (ido) inhibitors
|
|
WO2020110056A1
(en)
|
2018-11-30 |
2020-06-04 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds useful in hiv therapy
|
|
WO2020112700A1
(en)
|
2018-11-30 |
2020-06-04 |
Merck Sharp & Dohme Corp. |
9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
|
|
PT3886875T
(pt)
|
2018-11-30 |
2024-06-27 |
Juno Therapeutics Inc |
Métodos para tratamento utilizando terapia celular adotiva
|
|
AU2019392090A1
(en)
|
2018-12-03 |
2021-06-17 |
Agensys, Inc. |
Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
|
|
US11034710B2
(en)
|
2018-12-04 |
2021-06-15 |
Sumitomo Dainippon Pharma Oncology, Inc. |
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
|
EP3891270A1
(en)
|
2018-12-07 |
2021-10-13 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
|
|
WO2020115261A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
BR112021011224A2
(pt)
|
2018-12-11 |
2021-08-24 |
Theravance Biopharma R&D Ip, Llc |
Inibidores de alk5
|
|
WO2020120592A1
(en)
|
2018-12-12 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating melanoma
|
|
GB201820547D0
(en)
|
2018-12-17 |
2019-01-30 |
Oxford Univ Innovation |
Modified antibodies
|
|
US20220047556A1
(en)
|
2018-12-17 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sulconazole as a furin inhibitor
|
|
EP3897622B1
(en)
|
2018-12-18 |
2026-01-14 |
Merck Sharp & Dohme LLC |
Arginase inhibitors and methods of use
|
|
EP3898699A1
(en)
|
2018-12-19 |
2021-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
|
|
CN113438961A
(zh)
|
2018-12-20 |
2021-09-24 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
NL2024544B1
(en)
|
2018-12-21 |
2021-03-15 |
Aim Immunotech Inc |
Compositions And Methods For Cancer Therapy
|
|
BR112021012066A2
(pt)
|
2018-12-21 |
2021-11-03 |
Onxeo |
Novas moléculas de ácido nucleico conjugadas e seus usos
|
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
|
KR20210107731A
(ko)
|
2018-12-21 |
2021-09-01 |
노파르티스 아게 |
Pmel17에 대한 항체 및 이의 접합체
|
|
US20220025036A1
(en)
|
2018-12-21 |
2022-01-27 |
Novartis Ag |
Use of il-1beta binding antibodies
|
|
KR20210107730A
(ko)
|
2018-12-21 |
2021-09-01 |
노파르티스 아게 |
골수 형성이상 증후군의 치료 또는 예방에서의 il-1 베타 항체의 용도
|
|
JP2022514087A
(ja)
|
2018-12-21 |
2022-02-09 |
ノバルティス アーゲー |
ＩＬ－１β結合抗体の使用
|
|
WO2020127885A1
(en)
|
2018-12-21 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating cancers and resistant cancers
|
|
WO2020139871A1
(en)
|
2018-12-26 |
2020-07-02 |
Twist Bioscience Corporation |
Highly accurate de novo polynucleotide synthesis
|
|
MX2021007639A
(es)
|
2018-12-27 |
2021-08-11 |
Amgen Inc |
Formulaciones de virus liofilizadas.
|
|
CN113574386A
(zh)
|
2019-01-03 |
2021-10-29 |
国家医疗保健研究所 |
用于增强癌症患者的cd8+t细胞依赖性免疫应答的方法和药物组合物
|
|
FI3908281T3
(fi)
|
2019-01-09 |
2024-10-01 |
Celgene Corp |
Antiproliferatiivisia yhdisteitä ja toisia aktiivisia aineita käytettäväksi multippelin myelooman hoidossa
|
|
SG11202107439XA
(en)
|
2019-01-09 |
2021-08-30 |
Celgene Corp |
Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same
|
|
WO2020146441A1
(en)
|
2019-01-09 |
2020-07-16 |
Celgene Corporation |
Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
|
|
EA202191929A1
(ru)
*
|
2019-01-11 |
2021-09-23 |
Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи |
Днк-кодируемые моноклональные антитела, нацеленные на pd-1, для лечения и профилактики злокачественного заболевания
|
|
WO2020148338A1
(en)
|
2019-01-15 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
|
|
CN119700703A
(zh)
|
2019-01-17 |
2025-03-28 |
佐治亚技术研究公司 |
含有氧化的胆固醇的药物递送系统
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
SG11202107976SA
(en)
|
2019-01-29 |
2021-08-30 |
Juno Therapeutics Inc |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
|
ES3033655T3
(en)
|
2019-01-30 |
2025-08-06 |
Inst Nat Sante Rech Med |
Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor
|
|
EP3921031A1
(en)
|
2019-02-04 |
2021-12-15 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for modulating blood-brain barrier
|
|
MX2021009562A
(es)
|
2019-02-12 |
2021-09-08 |
Novartis Ag |
Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1.
|
|
KR20260008165A
(ko)
|
2019-02-12 |
2026-01-15 |
스미토모 파마 아메리카, 인크. |
헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
|
|
EP3924520A1
(en)
|
2019-02-13 |
2021-12-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
|
|
EP3924521A4
(en)
|
2019-02-15 |
2023-03-29 |
IncellDx, Inc. |
BLADDER-ASSOCIATED SAMPLES TESTING, IDENTIFICATION AND TREATMENT OF BLADDER-ASSOCIATED NEOPLASIA, AND KITS FOR USE THEREON
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
PH12021551976A1
(en)
|
2019-02-15 |
2022-07-04 |
Incyte Corp |
Cyclin-dependent kinase 2 biomarkers and uses thereof
|
|
CN113490528B
(zh)
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
|
GB2599228B
(en)
|
2019-02-21 |
2024-02-07 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
CN119039441A
(zh)
|
2019-02-21 |
2024-11-29 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
CN113766930B
(zh)
|
2019-02-26 |
2025-07-22 |
特韦斯特生物科学公司 |
Glp1受体的变异核酸文库
|
|
JP2022522668A
(ja)
|
2019-02-26 |
2022-04-20 |
ツイスト バイオサイエンス コーポレーション |
抗体を最適化するための変異体核酸ライブラリ
|
|
AU2020227824B2
(en)
|
2019-02-27 |
2025-07-10 |
Ionis Pharmaceuticals, Inc. |
Modulators of MALAT1 expression
|
|
MA55084A
(fr)
|
2019-02-28 |
2022-01-05 |
Regeneron Pharma |
Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau
|
|
EA202192420A1
(ru)
|
2019-03-05 |
2021-12-13 |
Эмджен Инк. |
Применение онколитических вирусов для лечения рака
|
|
TW202100520A
(zh)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
|
|
MX2021010560A
(es)
|
2019-03-06 |
2021-11-12 |
Regeneron Pharma |
Inhibidores de la via il-4/il-13 para una eficacia aumentada en el tratamiento de cancer.
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
WO2020183011A1
(en)
|
2019-03-14 |
2020-09-17 |
Institut Curie |
Htr1d inhibitors and uses thereof in the treatment of cancer
|
|
CN113795264A
(zh)
|
2019-03-19 |
2021-12-14 |
瓦尔希伯伦私人肿瘤研究基金会 |
采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法
|
|
WO2020191326A1
(en)
|
2019-03-20 |
2020-09-24 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (aml) with venetoclax failure
|
|
KR20210141621A
(ko)
|
2019-03-22 |
2021-11-23 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Pkm2 조정제를 포함하는 조성물 및 그를 사용한 치료 방법
|
|
KR20210146348A
(ko)
|
2019-03-28 |
2021-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
WO2020198676A1
(en)
|
2019-03-28 |
2020-10-01 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
TW202102543A
(zh)
|
2019-03-29 |
2021-01-16 |
美商安進公司 |
溶瘤病毒在癌症新輔助療法中之用途
|
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
|
CN118388628A
(zh)
|
2019-03-29 |
2024-07-26 |
居里研究所 |
具有经修饰的生物活性的白介素-2变体
|
|
EP3947737A2
(en)
|
2019-04-02 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
|
WO2020205688A1
(en)
|
2019-04-04 |
2020-10-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
|
US20220160692A1
(en)
|
2019-04-09 |
2022-05-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
|
|
EP3956446A1
(en)
|
2019-04-17 |
2022-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
|
|
WO2020220016A1
(en)
*
|
2019-04-26 |
2020-10-29 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Artificial antigen presenting cells comprising ligands for nkg2d for expanding immune cells for immunotherapy
|
|
EP3963109A1
(en)
|
2019-04-30 |
2022-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
|
WO2020227159A2
(en)
|
2019-05-03 |
2020-11-12 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity
|
|
JP2022536598A
(ja)
|
2019-05-07 |
2022-08-18 |
イミューニコム， インコーポレイテッド |
体外アフェレーシスによるチェックポイント阻害剤に対する応答の上昇
|
|
EP3969040A1
(en)
|
2019-05-13 |
2022-03-23 |
Regeneron Pharmaceuticals, Inc. |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
|
|
WO2020232378A1
(en)
|
2019-05-16 |
2020-11-19 |
Silicon Swat, Inc. |
Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
|
|
US20220227761A1
(en)
|
2019-05-16 |
2022-07-21 |
Stingthera, Inc. |
Oxoacridinyl acetic acid derivatives and methods of use
|
|
BR112021023345A2
(pt)
|
2019-05-20 |
2022-02-01 |
Pandion Operations Inc |
Imunotolerância com alvo em madcam
|
|
WO2020239558A1
(en)
|
2019-05-24 |
2020-12-03 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
|
KR20220016155A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
|
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
|
WO2020243570A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
KR20250126805A
(ko)
*
|
2019-06-05 |
2025-08-25 |
아납티스바이오, 아이엔씨. |
Pd-1 작용제 및 이의 사용 방법
|
|
US20210038684A1
(en)
|
2019-06-11 |
2021-02-11 |
Alkermes Pharma Ireland Limited |
Compositions and Methods for Cancer Immunotherapy
|
|
US20220251604A1
(en)
|
2019-06-14 |
2022-08-11 |
Tilt Biotherapeutics Oy |
Oncolytic adenovirus and checkpoint inhibitor combination therapy
|
|
EP3983444A4
(en)
*
|
2019-06-14 |
2023-10-25 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against pd-1 and methods of use thereof
|
|
KR20220041080A
(ko)
|
2019-06-18 |
2022-03-31 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
B형 간염 바이러스(hbv) 백신 및 항-pd-1 또는 항-pc-l1 항체의 조합
|
|
EP3986460A2
(en)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
|
|
JP7713393B2
(ja)
|
2019-06-21 |
2025-07-25 |
イミュニティーバイオ インコーポレイテッド |
多鎖キメラポリペプチドおよびその使用
|
|
US11332738B2
(en)
|
2019-06-21 |
2022-05-17 |
Twist Bioscience Corporation |
Barcode-based nucleic acid sequence assembly
|
|
EP3990635A1
(en)
|
2019-06-27 |
2022-05-04 |
Rigontec GmbH |
Design method for optimized rig-i ligands
|
|
SG11202111943UA
(en)
|
2019-07-02 |
2021-11-29 |
Hutchinson Fred Cancer Res |
Recombinant ad35 vectors and related gene therapy improvements
|
|
EP3994132A1
(en)
|
2019-07-03 |
2022-05-11 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
|
|
JP6881658B2
(ja)
|
2019-07-05 |
2021-06-02 |
小野薬品工業株式会社 |
Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CN110384657A
(zh)
*
|
2019-07-15 |
2019-10-29 |
三峡大学 |
靶向PD-L1载miR-34a微泡的制备方法及在制备抑制宫颈癌的药物上的应用
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
US12036204B2
(en)
|
2019-07-26 |
2024-07-16 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
|
US11083705B2
(en)
|
2019-07-26 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
|
JP7843695B2
(ja)
|
2019-08-02 |
2026-04-10 |
メルサナ セラピューティクス インコーポレイテッド |
がんの処置用のＳＴＩＮＧ（インターフェロン遺伝子刺激因子）アゴニストとしてのビス－［Ｎ－（（５－カルバモイル）－１Ｈ－ベンゾ［ｄ］イミダゾール－２－イル）－ピラゾール－５－カルボキサミド］誘導体および関連化合物
|
|
EP4007592A1
(en)
|
2019-08-02 |
2022-06-08 |
LanthioPep B.V. |
Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
US20220332825A1
(en)
|
2019-08-08 |
2022-10-20 |
Ono Pharmaceutical Co., Ltd. |
Bispecific protein
|
|
CA3149494A1
(en)
|
2019-08-12 |
2021-02-18 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
|
|
CA3150681A1
(en)
|
2019-08-14 |
2021-02-18 |
Incyte Corporation |
Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
|
GB201912107D0
(en)
|
2019-08-22 |
2019-10-09 |
Amazentis Sa |
Combination
|
|
TW202122420A
(zh)
|
2019-08-30 |
2021-06-16 |
美商艾吉納斯公司 |
抗ｃｄ９６抗體及其使用方法
|
|
WO2021048292A1
(en)
|
2019-09-11 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
JP2022549227A
(ja)
|
2019-09-17 |
2022-11-24 |
バイアル－アールアンドディー インベストメンツ ソシエダッド アノニマ |
医学的障害の治療における使用のための置換された飽和および不飽和ｎ－複素環式カルボキサミドおよび関連化合物
|
|
BR112022004791A2
(pt)
|
2019-09-17 |
2022-06-21 |
Bial R&D Invest S A |
Carboxamidas de imidazol substituídas e seu uso no tratamento de distúrbios médicos
|
|
KR20220100859A
(ko)
|
2019-09-17 |
2022-07-18 |
비알 - 알&디 인베스트먼츠, 에스.에이. |
산성 세라미다아제 저해제로서의 치환된 n-헤테로시클릭 카르복사미드, 및 약제로서의 이의 용도
|
|
WO2021053587A1
(en)
|
2019-09-18 |
2021-03-25 |
Klaus Strein |
Bispecific antibodies against ceacam5 and cd3
|
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
WO2021053556A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Nkg2d fusion proteins and uses thereof
|
|
WO2021055994A1
(en)
|
2019-09-22 |
2021-03-25 |
Bristol-Myers Squibb Company |
Quantitative spatial profiling for lag-3 antagonist therapy
|
|
EP4034566A4
(en)
|
2019-09-23 |
2024-01-24 |
Twist Bioscience Corporation |
VARIANT NUCLEIC ACID BANKS FOR CRTH2
|
|
JP2022548783A
(ja)
|
2019-09-23 |
2022-11-21 |
ツイスト バイオサイエンス コーポレーション |
単一ドメイン抗体のバリアント核酸ライブラリー
|
|
WO2021061837A1
(en)
|
2019-09-23 |
2021-04-01 |
President And Fellows Of Harvard College |
Biomaterial-based antigen free vaccine and the use thereof
|
|
AU2020351751A1
(en)
|
2019-09-25 |
2022-04-21 |
Seagen Inc. |
Combination anti-CD30 ADC, anti-PD-1 and chemotherapeutic for treatment of hematopoietic cancers
|
|
KR20220066950A
(ko)
|
2019-09-25 |
2022-05-24 |
브리스톨-마이어스 스큅 컴퍼니 |
암 요법을 위한 복합 바이오마커
|
|
KR20250127350A
(ko)
|
2019-09-26 |
2025-08-26 |
노파르티스 아게 |
항바이러스성 피라졸로피리디논 화합물
|
|
WO2021058711A2
(en)
|
2019-09-27 |
2021-04-01 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins
|
|
PE20221038A1
(es)
|
2019-09-30 |
2022-06-17 |
Incyte Corp |
Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores
|
|
CA3151322A1
(en)
|
2019-10-01 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11851466B2
(en)
|
2019-10-03 |
2023-12-26 |
Xencor, Inc. |
Targeted IL-12 heterodimeric Fc-fusion proteins
|
|
WO2021064180A1
(en)
|
2019-10-03 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating macrophages polarization
|
|
WO2021064184A1
(en)
|
2019-10-04 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
US11851426B2
(en)
|
2019-10-11 |
2023-12-26 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
CA3157361A1
(en)
|
2019-10-14 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021074391A1
(en)
|
2019-10-17 |
2021-04-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing nasal intestinal type adenocarcinomas
|
|
BR112022007179A2
(pt)
|
2019-10-21 |
2022-08-23 |
Novartis Ag |
Inibidores de tim-3 e usos dos mesmos
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
WO2021078910A1
(en)
|
2019-10-22 |
2021-04-29 |
Institut Curie |
Immunotherapy targeting tumor neoantigenic peptides
|
|
NL2024108B1
(en)
|
2019-10-26 |
2021-07-19 |
Vitroscan B V |
Methods and apparatus for measuring immune-cell mediated anti-tumoroid responses
|
|
WO2021083060A1
(zh)
|
2019-10-28 |
2021-05-06 |
中国科学院上海药物研究所 |
五元杂环氧代羧酸类化合物及其医药用途
|
|
EP4051286A1
(en)
|
2019-10-29 |
2022-09-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for treating uveal melanoma
|
|
EP4051278B1
(en)
|
2019-10-29 |
2025-12-17 |
Eisai R&D Management Co., Ltd. |
Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer
|
|
US20220390455A1
(en)
|
2019-11-05 |
2022-12-08 |
Bristol-Myers Squibb Company |
M-protein assays and uses thereof
|
|
JP2022554346A
(ja)
|
2019-11-05 |
2022-12-28 |
セルジーン コーポレーション |
２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドとの併用療法
|
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
US20220411499A1
(en)
|
2019-11-08 |
2022-12-29 |
Bristol-Myers Squibb Company |
LAG-3 Antagonist Therapy for Melanoma
|
|
CA3160131A1
(en)
|
2019-11-11 |
2021-05-20 |
Incyte Corporation |
Salts and crystalline forms of a pd-1/pd-l1 inhibitor
|
|
WO2021097256A1
(en)
|
2019-11-14 |
2021-05-20 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
|
EP3824954A1
(en)
|
2019-11-22 |
2021-05-26 |
Centre National de la Recherche Scientifique |
Device, apparatus and method for minibeam radiation therapy
|
|
KR20220104208A
(ko)
|
2019-11-22 |
2022-07-26 |
세라밴스 바이오파마 알앤디 아이피, 엘엘씨 |
Alk5 억제제로서 치환된 1,5-나프티리딘 또는 퀴놀린
|
|
US20230000864A1
(en)
|
2019-11-22 |
2023-01-05 |
Sumitomo Pharma Oncology, Inc. |
Solid dose pharmaceutical composition
|
|
US20210154281A1
(en)
|
2019-11-26 |
2021-05-27 |
Massachusetts Institute Of Technology |
Cell-based cancer vaccines and cancer therapies
|
|
EP4065157A1
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
JP7832891B2
(ja)
|
2019-12-04 |
2026-03-18 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤の誘導体
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
CN121422256A
(zh)
|
2019-12-04 |
2026-01-30 |
奥纳治疗公司 |
环状rna组合物和方法
|
|
EP4069683A1
(en)
|
2019-12-06 |
2022-10-12 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
|
KR20220114002A
(ko)
|
2019-12-09 |
2022-08-17 |
씨젠 인크. |
Liv1-adc 및 pd-1 길항제를 사용하는 병용 요법
|
|
BR112022011235A2
(pt)
|
2019-12-09 |
2022-12-13 |
Twist Bioscience Corp |
Bibliotecas de variantes de ácido nucleico para receptores de adenosina
|
|
JP7807076B2
(ja)
|
2019-12-13 |
2026-01-27 |
キュージーン インコーポレイテッド |
新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用
|
|
US20220396577A1
(en)
|
2019-12-17 |
2022-12-15 |
Merck Sharp & Dohme Llc |
Novel substituted 1,3-8-triazaspiro[4,5] decane-2,4-dione compounds as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (tdo) inhibitors
|
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
EP4077318B1
(en)
|
2019-12-18 |
2025-10-15 |
Ctxt Pty Ltd |
Benzimidazole dimers as modulators of sting
|
|
IL294085A
(en)
|
2019-12-19 |
2022-08-01 |
Bristol Myers Squibb Co |
Combinations of dgk inhibitors and checkpoint antagonists
|
|
EP4076508A1
(en)
|
2019-12-19 |
2022-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and vaccine compositions to treat cancers
|
|
BR112022011902A2
(pt)
|
2019-12-20 |
2022-09-06 |
Novartis Ag |
Terapias de combinação
|
|
US20210205311A1
(en)
|
2020-01-03 |
2021-07-08 |
Incyte Corporation |
Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
AU2020416273A1
(en)
|
2020-01-03 |
2022-07-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
EP4087583B1
(en)
|
2020-01-07 |
2026-04-22 |
Merck Sharp & Dohme LLC |
Arginase inhibitors and methods of use
|
|
WO2021146436A2
(en)
|
2020-01-14 |
2021-07-22 |
Synthekine, Inc. |
Biased il2 muteins methods and compositions
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
US20230076415A1
(en)
|
2020-01-17 |
2023-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
BR112022012310A2
(pt)
|
2020-01-17 |
2022-09-06 |
Novartis Ag |
Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
|
|
EP4096698A1
(en)
|
2020-01-28 |
2022-12-07 |
Genentech, Inc. |
Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer
|
|
CA3168923A1
(en)
|
2020-01-30 |
2021-08-05 |
ONA Therapeutics S.L. |
Combination therapy for treatment of cancer and cancer metastasis
|
|
EP4100126A1
(en)
|
2020-02-05 |
2022-12-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
|
|
JP2023514152A
(ja)
|
2020-02-06 |
2023-04-05 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｉｌ－１０およびその使用
|
|
EP4103599A1
(en)
|
2020-02-11 |
2022-12-21 |
HCW Biologics, Inc. |
Methods of activating regulatory t cells
|
|
KR20220140535A
(ko)
|
2020-02-11 |
2022-10-18 |
에이치씨더블유 바이올로직스, 인크. |
크로마토그래피 수지 및 이의 용도
|
|
US12115191B2
(en)
|
2020-02-11 |
2024-10-15 |
Immunitybio, Inc. |
Methods of treating age-related and inflammatory diseases
|
|
EP4107187A4
(en)
|
2020-02-21 |
2024-07-03 |
Pandion Operations, Inc. |
TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
|
|
WO2021171264A1
(en)
|
2020-02-28 |
2021-09-02 |
Novartis Ag |
Dosing of a bispecific antibody that binds cd123 and cd3
|
|
EP4110341A2
(en)
|
2020-02-28 |
2023-01-04 |
Novartis AG |
A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor
|
|
WO2021170777A1
(en)
|
2020-02-28 |
2021-09-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, prognosing and managing treatment of breast cancer
|
|
CN115484978A
(zh)
|
2020-03-05 |
2022-12-16 |
尼奥克斯医疗有限公司 |
使用免疫细胞治疗癌症的方法和组合物
|
|
US20230114276A1
(en)
|
2020-03-06 |
2023-04-13 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Modulating anti-tumor immunity
|
|
AU2021232158A1
(en)
|
2020-03-06 |
2022-09-29 |
Ona Therapeutics, S.L. |
Anti-CD36 antibodies and their use to treat cancer
|
|
WO2021178779A1
(en)
|
2020-03-06 |
2021-09-10 |
Incyte Corporation |
Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
|
|
WO2021183318A2
(en)
|
2020-03-09 |
2021-09-16 |
President And Fellows Of Harvard College |
Methods and compositions relating to improved combination therapies
|
|
JP7851254B2
(ja)
|
2020-03-20 |
2026-04-24 |
オルナ セラピューティクス インコーポレイテッド |
環状ｒｎａ組成物及び方法
|
|
AU2021244200A1
(en)
|
2020-03-23 |
2022-11-24 |
Bristol-Myers Squibb Company |
Anti-CCR8 antibodies for treating cancer
|
|
TW202204339A
(zh)
|
2020-03-31 |
2022-02-01 |
美商施萬生物製藥研發 Ip有限責任公司 |
經取代的嘧啶及使用方法
|
|
IL296901A
(en)
|
2020-04-02 |
2022-12-01 |
Mersana Therapeutics Inc |
Antibody-drug conjugates comprising sting agonists
|
|
JP2023522857A
(ja)
|
2020-04-10 |
2023-06-01 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂ細胞成熟抗原を標的とするキメラ抗原受容体によって操作された細胞療法に関する方法および使用
|
|
JP2023521227A
(ja)
|
2020-04-14 |
2023-05-23 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
癌の併用療法
|
|
AU2021256652A1
(en)
|
2020-04-14 |
2022-11-03 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer involving anti-ICOS and anti-PD1 antibodies, optionally further involving anti-tim3 antibodies
|
|
AU2021254794A1
(en)
|
2020-04-16 |
2022-12-15 |
Incyte Corporation |
Fused tricyclic KRAS inhibitors
|
|
IL296226A
(en)
|
2020-04-21 |
2022-11-01 |
Novartis Ag |
Dosing regimen for treating a disease modulated by csf-1r
|
|
TW202206100A
(zh)
|
2020-04-27 |
2022-02-16 |
美商西健公司 |
癌症之治療
|
|
EP4143231A1
(en)
|
2020-04-29 |
2023-03-08 |
HCW Biologics, Inc. |
Anti-cd26 proteins and uses thereof
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
WO2021224186A1
(en)
|
2020-05-04 |
2021-11-11 |
Institut Curie |
New pyridine derivatives as radiosensitizers
|
|
KR20230041654A
(ko)
|
2020-05-05 |
2023-03-24 |
테온 테라퓨틱스, 인크. |
칸나비노이드 수용체 유형 2 (cb2) 조정제 및 그의 용도
|
|
CR20220565A
(es)
|
2020-05-06 |
2023-01-13 |
Merck Sharp & Dohme Llc |
Inhibidores de il4i1 y métodos de uso
|
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
|
MX2022014191A
(es)
|
2020-05-13 |
2022-12-07 |
Massachusetts Inst Technology |
Composiciones de microdispositivos polimericos y su uso en la inmunoterapia de cancer.
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
EP4153628A1
(en)
|
2020-05-20 |
2023-03-29 |
Institut Curie |
Single domain antibodies and their use in cancer therapies
|
|
MX2022014734A
(es)
|
2020-05-26 |
2023-03-15 |
Regeneron Pharma |
Metodos de tratamiento del cancer de cuello uterino mediante la administracion del anticuerpo inhibidor de pd-1 cemiplimab.
|
|
MX2022014943A
(es)
|
2020-05-26 |
2023-03-08 |
Inst Nat Sante Rech Med |
Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna.
|
|
CR20220596A
(es)
|
2020-05-26 |
2023-01-23 |
Boehringer Ingelheim Int |
Anticuerpos anti-pd-1
|
|
CA3180060A1
(en)
|
2020-05-29 |
2021-12-02 |
Zongmin ZHAO |
Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
|
|
EP4157460A1
(en)
|
2020-06-01 |
2023-04-05 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
|
WO2021247003A1
(en)
|
2020-06-01 |
2021-12-09 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
|
US12024545B2
(en)
|
2020-06-01 |
2024-07-02 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
|
US11767353B2
(en)
|
2020-06-05 |
2023-09-26 |
Theraly Fibrosis, Inc. |
Trail compositions with reduced immunogenicity
|
|
EP4165041A1
(en)
|
2020-06-10 |
2023-04-19 |
Theravance Biopharma R&D IP, LLC |
Naphthyridine derivatives useful as alk5 inhibitors
|
|
JP2023529211A
(ja)
|
2020-06-11 |
2023-07-07 |
ノバルティス アーゲー |
Ｚｂｔｂ３２阻害剤及びその使用
|
|
TW202214857A
(zh)
|
2020-06-19 |
2022-04-16 |
法商昂席歐公司 |
新型結合核酸分子及其用途
|
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
US20230235077A1
(en)
|
2020-06-24 |
2023-07-27 |
The General Hospital Corporation |
Materials and methods of treating cancer
|
|
US20230255975A1
(en)
|
2020-06-25 |
2023-08-17 |
Celgene Corporation |
Methods for treating cancer with combination therapies
|
|
PE20231082A1
(es)
|
2020-06-26 |
2023-07-17 |
Amgen Inc |
Muteinas de il-10 y proteinas de fusion de las mismas referencia cruzada a solicitudes relacionadas
|
|
US20230355804A1
(en)
|
2020-06-29 |
2023-11-09 |
Flagship Pioneering Innovations V, Inc. |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
US20230235408A1
(en)
|
2020-06-30 |
2023-07-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
|
|
EP4172628A1
(en)
|
2020-06-30 |
2023-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
|
|
KR20230035576A
(ko)
|
2020-07-07 |
2023-03-14 |
비온테크 에스이 |
Hpv 양성 암 치료용 rna
|
|
DK4178548T3
(da)
|
2020-07-07 |
2024-08-19 |
Celgene Corp |
Farmaceutiske sammensætninger omfattende (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUORBENZONITRIL
|
|
WO2022009157A1
(en)
|
2020-07-10 |
2022-01-13 |
Novartis Ag |
Lhc165 and spartalizumab combinations for treating solid tumors
|
|
US20230266332A1
(en)
|
2020-07-28 |
2023-08-24 |
Inserm (Institut National De La Santè Et De La Recherch Médicale) |
Methods and compositions for preventing and treating a cancer
|
|
JP7819176B2
(ja)
|
2020-08-03 |
2026-02-24 |
ノバルティス アーゲー |
ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
CA3188732A1
(en)
*
|
2020-08-19 |
2022-02-24 |
Nathan HIGGINSON-SCOTT |
Multi-paratopic anti-pd-1 antibodies and uses thereof
|
|
KR20230056761A
(ko)
|
2020-08-26 |
2023-04-27 |
리제너론 파마슈티칼스 인코포레이티드 |
Pd-1 저해제의 투여에 의한 암 치료 방법
|
|
GB2616354A
(en)
|
2020-08-26 |
2023-09-06 |
Marengo Therapeutics Inc |
Methods of detecting TRBC1 or TRBC2
|
|
US11999752B2
(en)
|
2020-08-28 |
2024-06-04 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of KRAS
|
|
IL300813A
(en)
|
2020-08-28 |
2023-04-01 |
Bristol Myers Squibb Co |
LAG-3 antagonist therapy for hepatocellular carcinoma
|
|
AU2021334361A1
(en)
|
2020-08-31 |
2023-05-11 |
Bristol-Myers Squibb Company |
Cell localization signature and immunotherapy
|
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
WO2022049526A1
(en)
|
2020-09-02 |
2022-03-10 |
Pharmabcine Inc. |
Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer
|
|
CN116194142A
(zh)
|
2020-09-03 |
2023-05-30 |
瑞泽恩制药公司 |
通过施用pd-1抑制剂治疗癌症疼痛的方法
|
|
US12577621B2
(en)
|
2020-09-08 |
2026-03-17 |
Duke University |
LRRK2 mutations as biomarkers for the prediction of immune checkpoint response in cancer
|
|
JP2023544164A
(ja)
|
2020-10-02 |
2023-10-20 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
サイトカイン放出症候群の低減を伴うがんを治療するための抗体の組合せ
|
|
US11767320B2
(en)
|
2020-10-02 |
2023-09-26 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of KRAS
|
|
CN116406369A
(zh)
|
2020-10-05 |
2023-07-07 |
百时美施贵宝公司 |
用于浓缩蛋白质的方法
|
|
WO2022079270A1
(en)
|
2020-10-16 |
2022-04-21 |
Université D'aix-Marseille |
Anti-gpc4 single domain antibodies
|
|
CA3196243A1
(en)
|
2020-10-20 |
2022-04-28 |
Angela Marinetti |
Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
|
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
|
KR20230093282A
(ko)
|
2020-10-23 |
2023-06-27 |
브리스톨-마이어스 스큅 컴퍼니 |
폐암에 대한 lag-3 길항제 요법
|
|
MX2023004847A
(es)
|
2020-10-28 |
2023-07-11 |
Ikena Oncology Inc |
Combinación de un inhibidor del receptor de hidrocarburos de arilo (ahr) con un inhibidor de pdx o doxorrubicina.
|
|
TW202233185A
(zh)
|
2020-10-28 |
2022-09-01 |
日商衛材R&D企管股份有限公司 |
腫瘤治療用醫藥組合物
|
|
CA3199095A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
WO2022099018A1
(en)
|
2020-11-06 |
2022-05-12 |
Incyte Corporation |
Process of preparing a pd-1/pd-l1 inhibitor
|
|
TW202233615A
(zh)
|
2020-11-06 |
2022-09-01 |
美商英塞特公司 |
Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
|
|
CR20230230A
(es)
|
2020-11-06 |
2023-07-27 |
Incyte Corp |
Proceso para hacer un inhibidor de pd-1/pdl1 y sales y formas cristalinas del mismo
|
|
WO2022098972A1
(en)
|
2020-11-08 |
2022-05-12 |
Seagen Inc. |
Combination-therapy antibody drug conjugate with immune cell inhibitor
|
|
MX2023005570A
(es)
|
2020-11-12 |
2023-05-29 |
Inst Nat Sante Rech Med |
Anticuerpos conjugados o fusionados al dominio de union del receptor de la proteina de la espicula de sars-cov-2 y usos de los mismos con fines de vacunacion.
|
|
WO2022101463A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
|
|
US20230416830A1
(en)
|
2020-11-16 |
2023-12-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
US20230416838A1
(en)
|
2020-11-16 |
2023-12-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
US20230416196A1
(en)
|
2020-11-18 |
2023-12-28 |
Institut Curie |
Dimer of biguanidines and their therapeutic uses
|
|
TWI877433B
(zh)
|
2020-11-30 |
2025-03-21 |
大陸商杭州阿諾生物醫藥科技有限公司 |
用於治療ｐｉｋ３ｃａ突變癌症的組合療法
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
CA3204091A1
(en)
|
2020-12-08 |
2022-06-16 |
Infinity Pharmaceuticals, Inc. |
Eganelisib for use in the treatment of pd-l1 negative cancer
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
|
HRP20240213T1
(hr)
|
2020-12-18 |
2024-04-26 |
Lamkap Bio Beta Ag |
Bispecifična antitijela protiv ceacam5 i cd47
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
US20220233693A1
(en)
|
2020-12-28 |
2022-07-28 |
Bristol-Myers Squibb Company |
Antibody Compositions and Methods of Use Thereof
|
|
JP2024501029A
(ja)
|
2020-12-28 |
2024-01-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
|
|
TW202241441A
(zh)
|
2020-12-29 |
2022-11-01 |
美商英塞特公司 |
包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法
|
|
EP4274616A2
(en)
|
2021-01-11 |
2023-11-15 |
Synthekine, Inc. |
Compositions and methods related to receptor pairing
|
|
US20240317890A1
(en)
|
2021-01-14 |
2024-09-26 |
Institut Curie |
Her2 single domain antibodies variants and cars thereof
|
|
US20240141060A1
(en)
|
2021-01-29 |
2024-05-02 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
WO2022165260A1
(en)
|
2021-01-29 |
2022-08-04 |
Iovance Biotherapeutics, Inc. |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
US20240423972A1
(en)
|
2021-02-01 |
2024-12-26 |
Yale University |
Chemotherapeutic bioadhesive particles with immunostimulatory molecules for cancer treatment
|
|
CN117222413A
(zh)
|
2021-02-10 |
2023-12-12 |
同润生物医药(上海)有限公司 |
治疗肿瘤的方法和组合
|
|
WO2022174102A1
(en)
|
2021-02-12 |
2022-08-18 |
Synthorx, Inc. |
Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
|
|
CA3212345A1
(en)
|
2021-03-02 |
2022-09-09 |
Glaxosmithkline Intellectual Property Development Limited |
Substituted pyridines as dnmt1 inhibitors
|
|
CN117677634A
(zh)
|
2021-03-05 |
2024-03-08 |
利达提斯有限公司 |
三聚体多肽及其在治疗癌症中的用途
|
|
US11739144B2
(en)
|
2021-03-09 |
2023-08-29 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CLDN6
|
|
WO2022189618A1
(en)
|
2021-03-12 |
2022-09-15 |
Institut Curie |
Nitrogen-containing heterocycles as radiosensitizers
|
|
US20240165094A1
(en)
|
2021-03-17 |
2024-05-23 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating melanoma
|
|
US20240310266A1
(en)
|
2021-03-18 |
2024-09-19 |
Novartis Ag |
Biomarkers for cancer and methods of use thereof
|
|
AU2022239614A1
(en)
|
2021-03-19 |
2023-10-12 |
Icahn School Of Medicine At Mount Sinai |
Compounds for regulating trained immunity, and their methods of use
|
|
EP4313123A1
(en)
|
2021-03-23 |
2024-02-07 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
|
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
|
CN117858719A
(zh)
|
2021-03-29 |
2024-04-09 |
朱诺治疗学股份有限公司 |
使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法
|
|
JP2024511831A
(ja)
|
2021-03-31 |
2024-03-15 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
抗原結合タンパク質およびそれらの組み合わせ
|
|
EP4313109A1
(en)
|
2021-03-31 |
2024-02-07 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
TW202305009A
(zh)
|
2021-04-08 |
2023-02-01 |
美商默沙東有限責任公司 |
以皮下投予抗pd1抗體治療癌症之方法
|
|
WO2022217123A2
(en)
|
2021-04-08 |
2022-10-13 |
Nurix Therapeutics, Inc. |
Combination therapies with cbl-b inhibitor compounds
|
|
WO2022216993A2
(en)
|
2021-04-08 |
2022-10-13 |
Marengo Therapeutics, Inc. |
Multifuntional molecules binding to tcr and uses thereof
|
|
CA3215047A1
(en)
|
2021-04-09 |
2022-10-13 |
Lan Huang |
Therapeutic compositions and methods for treating tumors
|
|
EP4320160A1
(en)
|
2021-04-09 |
2024-02-14 |
Seagen Inc. |
Methods of treating cancer with anti-tigit antibodies
|
|
WO2022221170A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
TW202309022A
(zh)
|
2021-04-13 |
2023-03-01 |
美商努法倫特公司 |
用於治療具egfr突變之癌症之胺基取代雜環
|
|
EP4322938A1
(en)
|
2021-04-14 |
2024-02-21 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
New method to improve nk cells cytotoxicity
|
|
BR112023021475A2
(pt)
|
2021-04-16 |
2023-12-19 |
Novartis Ag |
Conjugados anticorpo-fármaco e métodos para produzir os mesmos
|
|
CN117597150A
(zh)
|
2021-04-20 |
2024-02-23 |
思进公司 |
抗体依赖性细胞毒性的调节
|
|
EP4326903A1
(en)
|
2021-04-23 |
2024-02-28 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
|
BR112023022439A2
(pt)
|
2021-04-26 |
2023-12-26 |
Celanese Eva Performance Polymers Llc |
Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
|
|
WO2022227015A1
(en)
|
2021-04-30 |
2022-11-03 |
Merck Sharp & Dohme Corp. |
Il4i1 inhibitors and methods of use
|
|
EP4337763A1
(en)
|
2021-05-10 |
2024-03-20 |
Institut Curie |
Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
|
|
WO2022239820A1
(ja)
|
2021-05-13 |
2022-11-17 |
公益財団法人神戸医療産業都市推進機構 |
炎症性疾患を治療又は予防するための抗ヒトｐｄ－１アゴニスト抗体及びこれを含有する医薬組成物
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
KR20240005794A
(ko)
*
|
2021-05-18 |
2024-01-12 |
쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 |
항 pd-1 폴리펩티드 및 그의 용도
|
|
WO2022242737A1
(zh)
|
2021-05-21 |
2022-11-24 |
天津立博美华基因科技有限责任公司 |
药物组合及其用途
|
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
|
TW202307210A
(zh)
|
2021-06-01 |
2023-02-16 |
瑞士商諾華公司 |
Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
|
|
EP4346904A1
(en)
|
2021-06-03 |
2024-04-10 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
|
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
|
US20240277842A1
(en)
|
2021-06-07 |
2024-08-22 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
CN115466329B
(zh)
*
|
2021-06-11 |
2025-09-12 |
广东菲鹏制药股份有限公司 |
一种抗pd-1人源化抗体及其应用
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
AU2022303363A1
(en)
|
2021-06-29 |
2024-01-18 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
WO2023280790A1
(en)
|
2021-07-05 |
2023-01-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
|
|
MX2024000357A
(es)
|
2021-07-07 |
2024-02-12 |
Incyte Corp |
Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
|
|
CA3225254A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
|
WO2023287896A1
(en)
|
2021-07-14 |
2023-01-19 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
|
US20250288666A1
(en)
|
2021-07-14 |
2025-09-18 |
Synthekine, Inc. |
Methods and compositions for use in cell therapy of neoplastic disease
|
|
IL310201A
(en)
|
2021-07-19 |
2024-03-01 |
Regeneron Pharma |
Combination of inhibitor-control inhibitor and oncolytic virus for cancer treatment
|
|
EP4377348A1
(en)
|
2021-07-30 |
2024-06-05 |
Seagen Inc. |
Treatment for cancer
|
|
KR20240042476A
(ko)
|
2021-07-30 |
2024-04-02 |
오엔에이 테라퓨틱스 에스.엘. |
항-cd36 항체 및 암을 치료하기 위한 이의 용도
|
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
|
EP4380596A1
(en)
|
2021-08-04 |
2024-06-12 |
Genentech, Inc. |
Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours
|
|
CA3227880A1
(en)
|
2021-08-05 |
2023-02-09 |
Marios SOTIROPOULOS |
Scanning dynamic device for minibeams production
|
|
CA3229448A1
(en)
|
2021-08-23 |
2023-03-02 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
|
US12441742B2
(en)
|
2021-08-31 |
2025-10-14 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of KRAS
|
|
TW202325306A
(zh)
|
2021-09-02 |
2023-07-01 |
美商天恩治療有限公司 |
改良免疫細胞之生長及功能的方法
|
|
EP4399206A1
(en)
|
2021-09-08 |
2024-07-17 |
Redona Therapeutics, Inc. |
Papd5 and/or papd7 inhibiting 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivatives
|
|
US20240391979A1
(en)
*
|
2021-09-13 |
2024-11-28 |
Achelois Biopharma, Inc. |
Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use
|
|
US20240316061A1
(en)
|
2021-09-17 |
2024-09-26 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
|
WO2023049697A1
(en)
|
2021-09-21 |
2023-03-30 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of kras
|
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
|
CA3234375A1
(en)
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
|
TW202327595A
(zh)
|
2021-10-05 |
2023-07-16 |
美商輝瑞大藥廠 |
用於治療癌症之氮雜內醯胺化合物的組合
|
|
EP4413040A1
(en)
|
2021-10-06 |
2024-08-14 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 in combination
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
CA3235146A1
(en)
|
2021-10-14 |
2023-04-20 |
Incyte Corporation |
Quinoline compounds as inhibitors of kras
|
|
WO2023066322A1
(zh)
|
2021-10-21 |
2023-04-27 |
杭州阿诺生物医药科技有限公司 |
一种融合多肽及其用途
|
|
KR20240099331A
(ko)
|
2021-10-28 |
2024-06-28 |
라이엘 이뮤노파마, 인크. |
면역 세포를 배양하기 위한 방법
|
|
CA3224890A1
(en)
|
2021-10-29 |
2023-05-04 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hematological cancer
|
|
US20240426823A1
(en)
|
2021-11-03 |
2024-12-26 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
|
WO2023079428A1
(en)
|
2021-11-03 |
2023-05-11 |
Pfizer Inc. |
Combination therapies using tlr7/8 agonist
|
|
WO2023081730A1
(en)
|
2021-11-03 |
2023-05-11 |
Teon Therapeutics, Inc. |
4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
|
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
|
KR20240099460A
(ko)
|
2021-11-11 |
2024-06-28 |
리제너론 파아마슈티컬스, 인크. |
Cd20-pd1 결합 분자 및 이의 사용 방법
|
|
AU2022384793A1
(en)
|
2021-11-12 |
2024-04-11 |
Advanced Accelerator Applications |
Combination therapy for treating lung cancer
|
|
CA3238283A1
(en)
|
2021-11-15 |
2023-05-19 |
Yangxin Fu |
Fusion protein construct taking interleukin 15 as active ingredient and use thereof
|
|
WO2023088968A1
(en)
|
2021-11-17 |
2023-05-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Universal sarbecovirus vaccines
|
|
WO2023089032A1
(en)
|
2021-11-19 |
2023-05-25 |
Institut Curie |
Methods for the treatment of hrd cancer and brca-associated cancer
|
|
MX2024006113A
(es)
|
2021-11-22 |
2024-07-29 |
Incyte Corp |
Terapia de combinación que comprende un inhibidor del receptor del factor de crecimiento de fibroblastos (fgfr) y un inhibidor del sarcoma de rata de kirsten (kras).
|
|
WO2023097211A1
(en)
|
2021-11-24 |
2023-06-01 |
The University Of Southern California |
Methods for enhancing immune checkpoint inhibitor therapy
|
|
WO2023099763A1
(en)
|
2021-12-03 |
2023-06-08 |
Institut Curie |
Sirt6 inhibitors for use in treating resistant hrd cancer
|
|
WO2023102184A1
(en)
|
2021-12-03 |
2023-06-08 |
Incyte Corporation |
Bicyclic amine compounds as cdk12 inhibitors
|
|
US12084453B2
(en)
|
2021-12-10 |
2024-09-10 |
Incyte Corporation |
Bicyclic amines as CDK12 inhibitors
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
KR20240133795A
(ko)
|
2021-12-16 |
2024-09-04 |
발레리오 테라퓨틱스 |
신규한 컨쥬게이티드 핵산 분자 및 이의 용도
|
|
EP4452327A1
(en)
|
2021-12-20 |
2024-10-30 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
|
EP4452257A1
(en)
|
2021-12-21 |
2024-10-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
EP4452982A1
(en)
|
2021-12-22 |
2024-10-30 |
Incyte Corporation |
Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
|
|
WO2023130081A1
(en)
|
2021-12-30 |
2023-07-06 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and vegf antagonist
|
|
WO2023133424A2
(en)
*
|
2022-01-05 |
2023-07-13 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides
|
|
US20230312718A1
(en)
|
2022-01-07 |
2023-10-05 |
Regeneron Pharmaceuticals, Inc |
Methods of Treating Recurrent Ovarian Cancer with Bispecific Anti-MUC16 x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies
|
|
KR20240135661A
(ko)
|
2022-01-26 |
2024-09-11 |
브리스톨-마이어스 스큅 컴퍼니 |
간세포성 암종에 대한 조합 요법
|
|
EP4469065A1
(en)
|
2022-01-28 |
2024-12-04 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
KR20240137086A
(ko)
|
2022-01-28 |
2024-09-19 |
조지아뮨 인코포레이티드 |
Pd-1 작용제인 세포예정사 단백질 1에 대한 항체
|
|
KR20240144944A
(ko)
|
2022-01-28 |
2024-10-04 |
온퀄리티 파마슈티컬스 차이나 리미티드 |
항종양제와 관련된 질병 또는 증상을 예방하거나 치료하는 방법
|
|
TW202523314A
(zh)
|
2022-02-14 |
2025-06-16 |
美商基利科學股份有限公司 |
抗病毒吡唑并吡啶酮化合物
|
|
WO2023154799A1
(en)
|
2022-02-14 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination immunotherapy for treating cancer
|
|
CN119677533A
(zh)
|
2022-02-17 |
2025-03-21 |
瑞泽恩制药公司 |
用于治疗癌症的检查点抑制剂与溶瘤病毒的组合
|
|
JP2025505812A
(ja)
|
2022-02-21 |
2025-02-28 |
オンクオリティ ファーマシューティカルズ チャイナ リミテッド |
化合物及びその用途
|
|
EP4482947A1
(en)
|
2022-02-24 |
2025-01-01 |
Amazentis SA |
Uses of urolithins
|
|
WO2023164638A1
(en)
|
2022-02-25 |
2023-08-31 |
Bristol-Myers Squibb Company |
Combination therapy for colorectal carcinoma
|
|
WO2023168363A1
(en)
|
2022-03-02 |
2023-09-07 |
HCW Biologics, Inc. |
Method of treating pancreatic cancer
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
JP2025512710A
(ja)
|
2022-03-07 |
2025-04-22 |
インサイト・コーポレイション |
Ｃｄｋ２阻害剤の固体形態、塩、ならびに調製プロセス
|
|
JP2025508076A
(ja)
|
2022-03-08 |
2025-03-21 |
アレンティス・セラピューティクス・アクチェンゲゼルシャフト |
Ｔ細胞の利用能を向上させるための抗クローディン－１抗体の使用
|
|
IL315405A
(en)
|
2022-03-17 |
2024-11-01 |
Regeneron Pharma |
Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies
|
|
WO2023178329A1
(en)
|
2022-03-18 |
2023-09-21 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
|
US20250302930A1
(en)
|
2022-03-24 |
2025-10-02 |
Institut Curie |
Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
|
|
EP4499677A1
(en)
|
2022-03-31 |
2025-02-05 |
Institut Curie |
Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
|
|
WO2023192478A1
(en)
|
2022-04-01 |
2023-10-05 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
WO2023194607A1
(en)
|
2022-04-07 |
2023-10-12 |
Institut Curie |
Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy
|
|
US20250241949A1
(en)
|
2022-04-07 |
2025-07-31 |
Institut Curie |
Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy
|
|
JP7851417B2
(ja)
|
2022-04-08 |
2026-04-24 |
ブリストル－マイヤーズ スクイブ カンパニー |
三次リンパ組織様構造の機械学習識別、分類、及び定量化
|
|
EP4507711A1
(en)
|
2022-04-13 |
2025-02-19 |
ImmunityBio, Inc. |
Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
EP4522657A1
(en)
|
2022-05-12 |
2025-03-19 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
|
WO2023224912A1
(en)
|
2022-05-16 |
2023-11-23 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
|
|
WO2023230554A1
(en)
|
2022-05-25 |
2023-11-30 |
Pfizer Inc. |
Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
|
|
CA3257502A1
(en)
|
2022-05-27 |
2023-11-30 |
Takeda Pharmaceutical Company Limited |
CD38 BINDING FUSION PROTEIN ASSAY
|
|
AR129423A1
(es)
|
2022-05-27 |
2024-08-21 |
Viiv Healthcare Co |
Compuestos útiles en la terapia contra el hiv
|
|
KR20250022071A
(ko)
|
2022-06-02 |
2025-02-14 |
브리스톨-마이어스 스큅 컴퍼니 |
항체 조성물 및 이의 이용 방법
|
|
WO2023240156A1
(en)
|
2022-06-08 |
2023-12-14 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
|
AU2023284958A1
(en)
|
2022-06-08 |
2025-01-02 |
Incyte Corporation |
Tricyclic triazolo compounds as dgk inhibitors
|
|
AU2023291779A1
(en)
|
2022-06-16 |
2024-10-17 |
Lamkap Bio Beta Ltd |
Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
|
|
AR129675A1
(es)
|
2022-06-22 |
2024-09-18 |
Incyte Corp |
Inhibidores de cdk12 de aminas biciclicas
|
|
EP4543923A1
(en)
|
2022-06-22 |
2025-04-30 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
|
AU2023300419A1
(en)
|
2022-07-01 |
2025-01-02 |
Transgene |
Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
|
|
US20240101557A1
(en)
|
2022-07-11 |
2024-03-28 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
|
US20260015356A1
(en)
|
2022-07-14 |
2026-01-15 |
Teon Therapeutics, Inc. |
Adenosine receptor antagonists and uses thereof
|
|
US12600722B2
(en)
|
2022-07-18 |
2026-04-14 |
Incyte Corporation |
Tetracyclic compounds as DGK inhibitors
|
|
US12600723B2
(en)
|
2022-07-18 |
2026-04-14 |
Incyte Corporation |
Tetracyclic compounds as DGK inhibitors
|
|
EP4310197A1
(en)
|
2022-07-21 |
2024-01-24 |
Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda |
Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
|
|
IL318426A
(en)
|
2022-08-02 |
2025-03-01 |
Regeneron Pharma |
Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and CD28 in combination with anti-PD-1 antibodies
|
|
JP2025525937A
(ja)
|
2022-08-05 |
2025-08-07 |
ジュノー セラピューティクス インコーポレイテッド |
Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体
|
|
EP4568670A1
(en)
|
2022-08-10 |
2025-06-18 |
Institut National de la Santé et de la Recherche Médicale |
Sigmar1 ligand for the treatment of pancreatic cancer
|
|
WO2024033400A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sk2 inhibitor for the treatment of pancreatic cancer
|
|
WO2024040175A1
(en)
|
2022-08-18 |
2024-02-22 |
Pulmatrix Operating Company, Inc. |
Methods for treating cancer using inhaled angiogenesis inhibitor
|
|
WO2024040264A1
(en)
|
2022-08-19 |
2024-02-22 |
Massachusetts Institute Of Technology |
Compositions and methods for targeting dendritic cell lectins
|
|
JPWO2024043319A1
(https=)
|
2022-08-26 |
2024-02-29 |
|
|
|
EP4583860A1
(en)
|
2022-09-06 |
2025-07-16 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
|
|
US20260061031A1
(en)
|
2022-09-14 |
2026-03-05 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
|
|
WO2024068617A1
(en)
|
2022-09-26 |
2024-04-04 |
Institut Curie |
Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy
|
|
US20260015416A1
(en)
|
2022-09-30 |
2026-01-15 |
Alentis Therapeutics Ag |
Treatment of drug-resistant hepatocellular carcinoma
|
|
AU2023356866A1
(en)
|
2022-10-03 |
2025-04-17 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies
|
|
US20240174732A1
(en)
|
2022-10-05 |
2024-05-30 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
|
|
EP4602078A2
(en)
|
2022-10-11 |
2025-08-20 |
Yale University |
Compositions and methods of using cell-penetrating antibodies
|
|
JP7730432B2
(ja)
|
2022-10-19 |
2025-08-27 |
アステラス製薬株式会社 |
がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用
|
|
EP4605422A2
(en)
|
2022-10-20 |
2025-08-27 |
Repertoire Immune Medicines, Inc. |
Cd8 t cell targeted il2
|
|
JP2025536252A
(ja)
|
2022-10-20 |
2025-11-05 |
アンセルム（アンスティチュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） |
癌治療のための併用療法
|
|
CN120380023A
(zh)
|
2022-10-20 |
2025-07-25 |
基础应用医学研究基金会 |
用于癌症治疗的纳米抗体
|
|
EP4605000A1
(en)
|
2022-10-21 |
2025-08-27 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of osteoarthritis
|
|
JP2026504619A
(ja)
|
2022-11-07 |
2026-02-06 |
ネオイミューンテック， インコーポレイテッド |
非メチル化ｍｇｍｔプロモーターを含む腫瘍を治療する方法
|
|
US20240217989A1
(en)
|
2022-11-18 |
2024-07-04 |
Incyte Corporation |
Heteroaryl Fluoroalkenes As DGK Inhibitors
|
|
CN120569191A
(zh)
|
2022-11-23 |
2025-08-29 |
乔治亚大学研究基金公司 |
用于增加免疫应答的组合物及其使用方法
|
|
TW202440639A
(zh)
|
2022-11-29 |
2024-10-16 |
大陸商杭州阿諾生物醫藥科技有限公司 |
一種融合多肽及其用途
|
|
EP4626552A1
(en)
|
2022-12-01 |
2025-10-08 |
MedImmune Limited |
Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
|
|
CN120302979A
(zh)
|
2022-12-01 |
2025-07-11 |
生物技术公司 |
针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗
|
|
KR20250135354A
(ko)
|
2022-12-13 |
2025-09-12 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Baff-r 및 cd19에 특이적인 키메라 항원 수용체 및 그의 방법 및 용도
|
|
JP2026501506A
(ja)
|
2022-12-14 |
2026-01-16 |
アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ |
Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
|
|
EP4638503A1
(en)
|
2022-12-21 |
2025-10-29 |
Bristol-Myers Squibb Company |
Combination therapy for lung cancer
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024150177A1
(en)
|
2023-01-11 |
2024-07-18 |
Advesya |
Treatment methods for solid tumors
|
|
TW202428575A
(zh)
|
2023-01-12 |
2024-07-16 |
美商英塞特公司 |
作為ｄｇｋ抑制劑之雜芳基氟代烯烴
|
|
CN120813375A
(zh)
|
2023-01-30 |
2025-10-17 |
凯玛布有限公司 |
抗体
|
|
EP4658687A1
(en)
|
2023-01-31 |
2025-12-10 |
University of Rochester |
Immune checkpoint blockade therapy for treating staphylococcus aureus infections
|
|
EP4680342A1
(en)
|
2023-03-13 |
2026-01-21 |
Regeneron Pharmaceuticals, Inc. |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
EP4683630A1
(en)
|
2023-03-21 |
2026-01-28 |
Institut Curie |
Vps4b inhibitor for use in methods for the treatment of hrd cancer
|
|
WO2024194673A1
(en)
|
2023-03-21 |
2024-09-26 |
Institut Curie |
Methods for the treatment of dedifferentiated liposarcoma
|
|
WO2024194402A1
(en)
|
2023-03-21 |
2024-09-26 |
Institut Curie |
Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
|
|
EP4689658A1
(en)
|
2023-03-28 |
2026-02-11 |
Institut National de la Santé et de la Recherche Médicale |
Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
|
|
AR132248A1
(es)
|
2023-03-29 |
2025-06-11 |
Merck Sharp & Dohme Llc |
Inhibidores de il4i1 y métodos para su uso
|
|
CN121620391A
(zh)
|
2023-04-06 |
2026-03-06 |
金麦安博股份有限公司 |
用于治疗癌症的针对pd-l1和cd137的多特异性结合剂
|
|
EP4694894A1
(en)
|
2023-04-12 |
2026-02-18 |
Agenus Inc. |
Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
|
|
EP4695290A1
(en)
|
2023-04-13 |
2026-02-18 |
Institut Curie |
Methods for the treatment of t-cell acute lymphoblastic leukemia
|
|
WO2024213767A1
(en)
|
2023-04-14 |
2024-10-17 |
Institut National de la Santé et de la Recherche Médicale |
Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
|
|
US20240390340A1
(en)
|
2023-04-18 |
2024-11-28 |
Incyte Corporation |
Pyrrolidine kras inhibitors
|
|
WO2024223299A2
(en)
|
2023-04-26 |
2024-10-31 |
Isa Pharmaceuticals B.V. |
Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
|
|
EP4704807A1
(en)
|
2023-05-03 |
2026-03-11 |
IOX Therapeutics Limited |
Inkt cell modulator liposomal compositions and methods of use
|
|
WO2024231384A1
(en)
|
2023-05-10 |
2024-11-14 |
Institut National de la Santé et de la Recherche Médicale |
Compositions for treating senescence related disease
|
|
EP4709756A1
(en)
|
2023-05-10 |
2026-03-18 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
TW202509071A
(zh)
|
2023-05-12 |
2025-03-01 |
丹麥商珍美寶股份有限公司 |
能夠與ｏｘ４０結合之抗體、其變異體及其用途
|
|
WO2024245951A1
(en)
|
2023-05-26 |
2024-12-05 |
Institut National de la Santé et de la Recherche Médicale |
Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
|
|
WO2024254245A1
(en)
|
2023-06-09 |
2024-12-12 |
Incyte Corporation |
Bicyclic amines as cdk2 inhibitors
|
|
WO2024256635A1
(en)
|
2023-06-15 |
2024-12-19 |
Institut National de la Santé et de la Recherche Médicale |
Dpm1 inhibitor for treating cancer
|
|
WO2024261302A1
(en)
|
2023-06-22 |
2024-12-26 |
Institut National de la Santé et de la Recherche Médicale |
Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
|
|
EP4731681A1
(en)
|
2023-06-23 |
2026-04-29 |
Imcheck Therapeutics |
Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
|
|
WO2025003193A1
(en)
|
2023-06-26 |
2025-01-02 |
Institut National de la Santé et de la Recherche Médicale |
Sertraline and indatraline for disrupting intracellular cholesterol trafficking and subsequently inducing lysosomal damage and anti-tumor immunity
|
|
WO2025006811A1
(en)
|
2023-06-27 |
2025-01-02 |
Lyell Immunopharma, Inc. |
Methods for culturing immune cells
|
|
KR20260047513A
(ko)
|
2023-06-30 |
2026-04-08 |
머크 샤프 앤드 돔 엘엘씨 |
접합체를 포함하는 제약 조합물의 치료방법 및 용도
|
|
CN121443321A
(zh)
|
2023-06-30 |
2026-01-30 |
默沙东有限责任公司 |
治疗组合及其用途和治疗方法
|
|
WO2025012417A1
(en)
|
2023-07-13 |
2025-01-16 |
Institut National de la Santé et de la Recherche Médicale |
Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
|
|
KR20260049559A
(ko)
|
2023-08-02 |
2026-04-14 |
리제너론 파아마슈티컬스, 인크. |
이중특이적 항-PSMA x 항-CD28 항체를 이용한 투명 세포 신세포 암종의 치료 방법
|
|
IL325956A
(en)
|
2023-08-02 |
2026-03-01 |
Regeneron Pharma |
Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and CD28
|
|
AU2024326076A1
(en)
|
2023-08-15 |
2026-02-12 |
Gilead Sciences, Inc. |
Treatment of non-small cell lung cancer using sacituzumab govitecan and an anti-pd-1 antibody or antigen binding fragment thereof
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
CN121712524A
(zh)
|
2023-08-18 |
2026-03-20 |
百时美施贵宝公司 |
包含结合bcma和cd3的抗体的组合物以及治疗方法
|
|
WO2025043151A2
(en)
|
2023-08-24 |
2025-02-27 |
Incyte Corporation |
Bicyclic dgk inhibitors
|
|
AU2024330458A1
(en)
|
2023-09-01 |
2026-02-12 |
Amgen Inc. |
Molecules for treatment of cancer
|
|
WO2025051895A1
(en)
|
2023-09-06 |
2025-03-13 |
Novimmune Sa |
Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
WO2025068393A1
(en)
|
2023-09-27 |
2025-04-03 |
Institut Curie |
Methods for the treatment of fibrotic related diseases
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|
|
US20250114346A1
(en)
|
2023-10-09 |
2025-04-10 |
Incyte Corporation |
Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
|
|
WO2025080538A1
(en)
|
2023-10-09 |
2025-04-17 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine
|
|
WO2025078632A1
(en)
|
2023-10-12 |
2025-04-17 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from cancer
|
|
TW202515903A
(zh)
|
2023-10-12 |
2025-04-16 |
瑞士商百濟神州瑞士有限責任公司 |
手術前後基於抗ｐｄ－１之治療
|
|
CN121969389A
(zh)
|
2023-10-13 |
2026-05-01 |
吉利德科学公司 |
用于治疗癌症的联合疗法
|
|
WO2025088496A1
(en)
|
2023-10-24 |
2025-05-01 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
|
|
WO2025096738A1
(en)
|
2023-11-01 |
2025-05-08 |
Incyte Corporation |
Kras inhibitors
|
|
WO2025093824A1
(en)
|
2023-11-02 |
2025-05-08 |
Tilt Biotherapeutics Oy |
Oncolytic adenovirus, immune checkpoint inhibitor and chemoterapeutic agent combination therapy of cancer
|
|
AU2024373478A1
(en)
|
2023-11-03 |
2026-04-16 |
Amgen Inc. |
Bispecific molecules
|
|
AU2024379466A1
(en)
|
2023-11-15 |
2026-04-23 |
Regeneron Pharmaceuticals, Inc. |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
|
|
TW202539732A
(zh)
|
2023-11-29 |
2025-10-16 |
美商再生元醫藥公司 |
以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法
|
|
TW202540189A
(zh)
|
2023-11-30 |
2025-10-16 |
德商生物新技術公司 |
在組合療法中能夠結合ｏｘ４０之抗體
|
|
TW202523667A
(zh)
|
2023-12-05 |
2025-06-16 |
美商英塞特公司 |
作為ｄｇｋ抑制劑之三環三唑并化合物
|
|
TW202523304A
(zh)
|
2023-12-06 |
2025-06-16 |
美商英塞特公司 |
包含ｄｇｋ抑制劑及ｐｄ—１／ｐｄ—ｌ１抑制劑之組合療法
|
|
WO2026033885A1
(en)
|
2024-08-08 |
2026-02-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
TW202541837A
(zh)
|
2023-12-08 |
2025-11-01 |
日商安斯泰來製藥公司 |
含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
TW202542187A
(zh)
|
2023-12-12 |
2025-11-01 |
美商再生元醫藥公司 |
以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法
|
|
US20250195536A1
(en)
|
2023-12-13 |
2025-06-19 |
Incyte Corporation |
Bicyclooctane kras inhibitors
|
|
WO2025132479A1
(en)
|
2023-12-18 |
2025-06-26 |
Institut National de la Santé et de la Recherche Médicale |
Flt3 inhibitor for modulating macrophages polarization
|
|
EP4574165A1
(en)
|
2023-12-21 |
2025-06-25 |
Egle Therapeutics |
Immunocytokine for cancer treatment
|
|
WO2025133175A1
(en)
|
2023-12-21 |
2025-06-26 |
Egle Therapeutics |
Immunocytokine for cancer treatment
|
|
WO2025132770A1
(en)
|
2023-12-22 |
2025-06-26 |
Institut National de la Santé et de la Recherche Médicale |
Affitins for the treatment of cancer
|
|
WO2025145207A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg-depleting agent
|
|
WO2025153834A1
(en)
|
2024-01-19 |
2025-07-24 |
Institut National de la Santé et de la Recherche Médicale |
Methods of predicting the risk of recurrence and/or death of patients suffering from a hepatocellular carcinoma (hcc)
|
|
WO2025158077A1
(en)
|
2024-01-26 |
2025-07-31 |
Institut Curie |
Lipid degraders to trigger ferroptosis in cancer
|
|
TW202545567A
(zh)
|
2024-01-30 |
2025-12-01 |
美商思進公司 |
抗ｐｄ－ｌ１抗體和抗體－藥物共軛體及彼等在治療癌症的用途
|
|
WO2025174825A2
(en)
|
2024-02-12 |
2025-08-21 |
Aera Therapeutics, Inc. |
Delivery compositions
|
|
US12521446B2
(en)
|
2024-02-27 |
2026-01-13 |
Bristol-Myers Squibb Company |
Anti-CEACAM5 antibody drug conjugates
|
|
WO2025184208A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
WO2025202222A1
(en)
|
2024-03-25 |
2025-10-02 |
Institut National de la Santé et de la Recherche Médicale |
Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells
|
|
TW202602455A
(zh)
|
2024-03-26 |
2026-01-16 |
美商安進公司 |
使用ｍｔａ協作的ｐｒｍｔ５抑制劑的癌症治療
|
|
WO2025202213A1
(en)
|
2024-03-26 |
2025-10-02 |
Institut National de la Santé et de la Recherche Médicale |
Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
|
|
WO2025202450A1
(en)
|
2024-03-28 |
2025-10-02 |
Institut Curie |
Myeloid cells modified by cytokine chimeric receptor and uses thereof
|
|
EP4624494A1
(en)
|
2024-03-29 |
2025-10-01 |
Institut Curie |
Her2 single domain antibody and uses thereof
|
|
WO2025210123A1
(en)
|
2024-04-03 |
2025-10-09 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for treating cancers
|
|
WO2025210175A1
(en)
|
2024-04-04 |
2025-10-09 |
Centre National De La Recherche Scientifique |
Mutant csf-1r extracellular domain fusion molecules and therapeutic uses thereof
|
|
WO2025210252A1
(en)
|
2024-04-05 |
2025-10-09 |
Institut Curie |
Modulators of fam118b protein for use in therapy
|
|
WO2025213154A1
(en)
|
2024-04-05 |
2025-10-09 |
Amgen Inc. |
Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors
|
|
WO2025219330A1
(en)
|
2024-04-15 |
2025-10-23 |
Institut National de la Santé et de la Recherche Médicale |
Detection of ppix for use in methods for melanoma ferroptosis sensitivity and targeted therapy resistance prediction
|
|
WO2025219595A1
(en)
|
2024-04-19 |
2025-10-23 |
Biper Therapeutics |
Method for combination treatments using alkynylbenzenesulphonamides for cancer therapy
|
|
WO2025223372A1
(en)
|
2024-04-22 |
2025-10-30 |
Fujian Haixi Pharmaceuticals Co., Ltd. |
Combination comprising a pd-1 inhibitor and a pyridine compound for use in treating solid tumors
|
|
WO2025228998A1
(en)
|
2024-04-30 |
2025-11-06 |
Institut National de la Santé et de la Recherche Médicale |
Use of hdac4 inhibitors for the treatment of melanoma
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|
|
WO2025247829A1
(en)
|
2024-05-27 |
2025-12-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for treating prostate cancer
|
|
WO2025252857A1
(en)
|
2024-06-05 |
2025-12-11 |
Institut National de la Santé et de la Recherche Médicale |
Il-15 muteins with ph-dependent binding for il-15ralpha
|
|
WO2025252855A1
(en)
|
2024-06-05 |
2025-12-11 |
Institut National de la Santé et de la Recherche Médicale |
IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta
|
|
WO2025259515A2
(en)
|
2024-06-11 |
2025-12-18 |
Amgen Inc. |
Combination treatment
|
|
WO2026006604A1
(en)
|
2024-06-26 |
2026-01-02 |
Lyell Immunopharma, Inc. |
Feeder cell replacement
|
|
WO2026003224A2
(en)
|
2024-06-26 |
2026-01-02 |
Iomx Therapeutics Ag |
Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
|
|
WO2026008009A1
(en)
*
|
2024-07-04 |
2026-01-08 |
Xiamen Jiuheyipin Biopharmaceutical Co., Ltd. |
Pd-1 targeting antibodies and uses thereof
|
|
WO2026012976A1
(en)
|
2024-07-08 |
2026-01-15 |
Institut National de la Santé et de la Recherche Médicale |
Use of inhibitor of gasdermind for treatment of rac2 monogenic disorders
|
|
WO2026015612A1
(en)
|
2024-07-10 |
2026-01-15 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating smarcb1-deficient cancers
|
|
EP4681780A1
(en)
|
2024-07-18 |
2026-01-21 |
Egle Therapeutics |
Immunocytokine for cancer treatment
|
|
WO2026017820A1
(en)
|
2024-07-18 |
2026-01-22 |
Egle Therapeutics |
Fusion protein for cancer treatment
|
|
WO2026035860A1
(en)
|
2024-08-07 |
2026-02-12 |
Teon Therapeutics, Inc. |
Formulations of adenosine receptor antagonist
|
|
WO2026037841A1
(en)
|
2024-08-12 |
2026-02-19 |
ONA Therapeutics S.L. |
Anti-fgfr4 molecules and uses thereof
|
|
US20260049118A1
(en)
|
2024-08-19 |
2026-02-19 |
HCW Biologics, Inc. |
Single-chain chimeric polypeptides and uses thereof
|
|
WO2026043906A1
(en)
|
2024-08-19 |
2026-02-26 |
HCW Biologics, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
|
WO2026050572A2
(en)
|
2024-08-29 |
2026-03-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|
|
EP4707295A1
(en)
|
2024-09-05 |
2026-03-11 |
Egle Therapeutics |
Interleukin-2 variants with modified biological activity
|
|
EP4707296A1
(en)
|
2024-09-05 |
2026-03-11 |
Egle Therapeutics |
Interleukin-2 variants with modified biological activity
|
|
WO2026052851A2
(en)
|
2024-09-09 |
2026-03-12 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitor of ciliogenesis for use in a method of preventing therapeutic resistance in cancer
|
|
WO2026059920A1
(en)
|
2024-09-10 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bcma inhibitors in combination with pd1/pd-l1 inhibitors
|
|
US20260069605A1
(en)
|
2024-09-11 |
2026-03-12 |
Incyte Corporation |
Kras inhibitors
|
|
WO2026057739A1
(en)
|
2024-09-12 |
2026-03-19 |
BioNTech SE |
Combination therapy comprising anti-ctla4 antibodies and anti-pd-1 antibodies for platinum-resistant ovarian cancer treatment
|
|
WO2026072557A2
(en)
|
2024-09-24 |
2026-04-02 |
Genzyme Corporation |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
|
US20260098044A1
(en)
|
2024-10-04 |
2026-04-09 |
Incyte Corporation |
Tricyclic heteroaryl compounds as inhibitors of tyk2 and/or jak1
|
